



Prostate Cancer
Foundation
Curing Together.

Strength, Gratitude, & Heroes



2019-20 Annual Report

2019–20 Annual Report

Mission Statement

PCF funds the world's most promising research to improve the prevention, detection, and treatment of prostate cancer and ultimately cure it for good.



Prostate Cancer
Foundation
Curing Together.

Strength, Gratitude, & Heroes

There is no doubt about it: 2020 started in an unexpected way. A new enemy emerged, and it made us that much more thankful for old friends and family. Whether your hero is your dad, your doctor, or your spouse, this is the time for a renewed investment in gratitude for both small moments and monumental achievement.

2019 saw 3 new FDA approvals for prostate cancer. Two more arrived in 2020, and an additional approval is expected later this year. At PCF, we continue to fight prostate cancer without reservation. Our mission is to ensure that families have more days together and – as with every challenge we rip through at PCF – science will prevail in these trying times.

Thanks to the generous donations of people like you, more than 600 PCF researchers at nearly 100 institutions are actively using cutting-edge science to discover new therapies and solve the toughest prostate cancer problems to keep you safe, for a long time to come.



bbb.org/charity

PCF meets all 20 of the Better Business Bureau's standards for charity accountability.



PCF has been designated a Top-Rated Charity by Charity Watch.

Table of Contents

A Message From our President and CEO	4
PCF in 2019: By the Numbers	8
Early Investment Hits the Jackpot	10
PCF Fundraising Community	12
Renowned Actor Harry Lennix Teams With PCF for National Minority Health Month	14
The NBA Doubles Down on Assisting Men With Prostate Cancer	15
Finding Prostate Cancer Earlier... and (Much) Earlier	16
Extraordinary Care for Veterans	18
Leveraging Relationships and Passion Into Research Dollars	20
Movember: Accelerating Science Together	22
The Jerry II: Golf for Good – Honoring a Hollywood Legend	23
2019 Home Run Challenge: The Dickson Family and PCF Team Up for a Cure!	24
A Patient’s Journey: Sheffler Strong	26
Accelerating Women in Science	28
PCF Catalyzes the Development of a Polygenic Test for African American Men at Highest Risk	29
Supporting Cures	30
2019 Donor Roll	31
2019 Research Awards	38
2019 Financials	42
2019 Supporting Partners	46
Board of Directors and Leadership Team	47



A Message From our President and CEO

Dear friends,

We hope that you are safe and well. Prostate cancer has not stopped in the pandemic, and neither has PCF.

All over the world, lives have been completely changed. Many people have lost jobs, familiar routines, financial security – even loved ones – to the virus. **But for those battling prostate cancer during this time, the changes can present an entirely different level of complication and anxiety.**

Since the moment this crisis began, PCF has been working 7 days a week, adjusting our priorities, to best serve the patients and families who look to us for information and breakthrough advances in treatment. Over 15 PCF-funded researchers and teams pivoted to work on projects aimed at preventing deaths from COVID-19 using their deep expertise on how to fast-forward anti-COVID-19 drugs.

Here's just one example. In January, German scientists discovered that one of the ways SARS-CoV-2 fatally infects the lungs is by using a “door handle” protein called TMPRSS2. This receptor protein is required for the coronavirus to enter lung cells. TMPRSS2 is also a key drug target in prostate cancer bone metastasis and has received millions of dollars of PCF research funding starting in 1998 and right up through 2020. Because TMPRSS2 is a longstanding PCF drug research target (over 900 publications), in just under 4 weeks, thanks to round-the-clock Zoom meetings and emails, multiple prostate cancer researchers in the PCF research enterprise collaborated with infectious disease experts to test their anti-TMPRSS2 drug approaches against COVID-19. This occurred globally in PCF laboratories and with breathtaking speed in emergency clinical trials in the U.S., Denmark, Italy, Japan, Germany, and Great Britain.

As we continue to fund the life-extending and life-saving research that is so urgently needed by prostate cancer patients, we've simultaneously shifted our focus in some other very targeted ways, to do our part to help our patients and our healthcare workers get through this crisis, safely. Here are just a few actions PCF has taken to help patients weather this storm:

- 1. Returning patients to their treatment plan.** Until our hospitals and clinics are safe for health care workers, they'll never be safe for you and me. PCF-funded Young Investigator Dr. James Byrne, who has both an oncology and engineering background, is part of team of scientists at MIT who have rapidly redeployed their skills to build a better mask for COVID-19, fast. Dr. Byrne and team have developed a way to cheaply mass-produce masks that can be re-sterilized by basic methods. This is an important step in ensuring healthcare providers have the protection they need to treat prostate cancer patients. Eventually, we hope this mask would be available to anyone visiting a health care facility, including patients and caregivers. Learn more at join.pcf.org/mask.
- 2. Providing the most up-to-date, targeted information about COVID-19 for prostate cancer patients.** pcf.org/COVID-19 is updated constantly with information about how your treatment may change during the pandemic. This includes Facebook LIVE broadcasts with me, podcasts with Mike Milken, and conversations with some of our researchers on the front lines, including medical oncologists **Dr. Alicia Morgans** and **Dr. Tanya Dorff**. We're still learning about the COVID-19 disease, day by day, and PCF is bringing this information to our audience of patients and families in real time.
- 3. Keeping our researchers working.** Mentorship is a hallmark of PCF's success with breakthrough research. We fund many incredible young investigators (YIs) who are thinking outside the box on how to attack prostate cancer – and even COVID-19 (see above). Some are looking to us for extra mentorship as they navigate trying to do research in this storm – even just to keep their experiments going. Others are directly caring for COVID-19 patients. Our science team, led by Chief Science Officer Dr. Howard Soule, has reached out (digitally!) to *all* of our YIs to offer support, advice, or just listen. We want them to hit the ground running when this crisis passes.
- 4. Focusing on patient care.** The most respected resource patients have is the **PCF Prostate Cancer Patient Guide**, edited by 15 of the world's leading clinicians. This free roadmap of how to deal with your prostate cancer treatment and recovery, no matter the stage, has been hailed by patients and doctors alike as a must-have. Although we will delay releasing a new *printed* version of the guide until this pandemic subsides, we will continue our commitment to update the guide for download at least 2 times per year, making it truly the most current and comprehensive resource you can get on prostate cancer. We recently released our first update of 2020: an appendix dedicated entirely to "Your Care During the COVID-19 Pandemic," including specific notes for every stage of the prostate cancer journey.

At the same time as this extraordinary work is continuing, we acknowledge that there are even more unprecedented real-world problems created by this pandemic. Today, as I write this letter,

Prostate cancer has not stopped in the pandemic. Neither has PCF.

Since the moment this crisis began, PCF has been working 7 days a week, adjusting our priorities, to best serve the patients and families who look to us for information and breakthrough advances in treatment.

we are getting emails from men newly diagnosed with prostate cancer who are scared because their treatment is being delayed. It's not easy, but we take some solace in the fact that many of these men will still have a good outcome – in part because prostate cancer is slow-growing, and in part because, over the years, PCF-funded advances in science have multiplied the number of treatment options that will be available when things return to normal.

In fact, 2019 was one of the most prolific years for new drug advances and approvals, bringing us a giant step closer to achieving PCF's mission to ending all death and suffering from prostate cancer. The U.S. prostate cancer death rate decreased

again by another 3.1%. Compared with the year Mike Milken was diagnosed and founded PCF, the death rate has been reduced by 52.2%. Simply put: vastly more men are alive.

Translating PCF research from concept to clinic does not happen overnight – it takes years of team collaboration, individual creativity, and grinding work in the lab. 2019 was a remarkable year in terms of the number of practice-changing medicines to help patients. This is the ultimate metric of progress in cancer research. In total, PCF funded the earliest stage R+D for 7 such changes (including 3 new FDA approvals):

1. **Apalutamide:** FDA-approved for men with metastatic prostate cancer that is responsive to hormone therapy. In a clinical trial, this drug lowered the risk of death by 33%.
2. **Enzalutamide:** FDA-approved for men with metastatic hormone-sensitive prostate cancer. Compared with placebo, men taking enzalutamide were 33% less likely to die.
3. **Darolutamide:** FDA-approved for men with prostate cancer that is not responsive to hormone therapy and with no visible metastases upon imaging. The drug more than doubled the time men lived without metastasis.
4. **Cabazitaxel:** shown to slow cancer growth in men with metastatic disease that is resistant to hormone therapy and who have progressed on other treatments – a patient population that has historically had few options.
5. In a demonstration of the power of precision oncology, the drug **olaparib** was shown in a clinical trial to delay disease progression or death compared with standard-of-care treatments.

6. A **new understanding** of metastatic disease and a **new use of radiation therapy** in men with a low number of metastases showed that focused radiation directed to the metastases resulted in lower rates of progression.
7. Sometimes, the best treatment is less treatment. A **fresh look at data** from a large randomized trial revealed that among patients with recurrent prostate cancer receiving radiation therapy, PSA can be used to determine which men need hormone therapy as well. If the PSA is low, no hormone therapy is needed.


Beyond research, 2019 was also the greatest year ever for outreach to men with prostate cancer, with our patient education and communications efforts extending further than any other year in PCF's history:

- ▶ Web traffic increased 30% and social traffic increased by 200%
- ▶ Over 100,000 informational guides distributed
- ▶ Creation of a new guide for the whole family, ***The Science of Living Well, Beyond Cancer***
- ▶ Over 500 pieces of public-facing content created, including articles, blog posts, videos, social media posts, patient stories, and direct emails to patients and families
- ▶ 37% increase in new donors who gave from \$5 to \$1,000,000
- ▶ PCF's awareness campaign, "Light It Blue," touched the entire country: in September 2019, all 50 states had at least one building lit blue for Prostate Cancer Awareness Month

Inside, you'll find a look back at a scientifically stunning 2019, and a look forward at 4 groundbreaking research thrusts we're working towards globally in 2020: 2 new precision medicines that target weaknesses in tumor cells; new imaging technology with the promise to detect smaller cancers earlier; and a new saliva test to assess a man's lifetime prostate cancer risk.

Thank you for your enduring interest in ending death and suffering from prostate cancer. Please stay safe, cheerfully distant, and digitally close – and where possible – give those you love an extra tight hug.

In service,



Jonathan W. Simons, MD

President and Chief Executive Officer

PCF IN 2019

BY THE NUMBERS

7 improvements funded in standard-of-care- or paradigm-changing clinical trials, elevating the standard of care for patients with advanced metastatic disease



205 impactful PCF-funded researcher publications




17 Challenge Awards
30 Young Investigator Awards
8 PCF VALor Awards
38 First-time Awardees



558 multi-disciplinary researchers collaborating at PCF's Annual Scientific Retreat

Breakthroughs in Prostate Cancer Treatment and Practice



77,871



PCF-published *Prostate Cancer Patient Guide* copies distributed to

ensure that men and their families have access to the most comprehensive, updated information available

52%

DECLINE IN DEATHS FROM PROSTATE CANCER SINCE PCF'S FOUNDDING



3 FDA drug approvals with early-stage funding from PCF



500+

pieces of content created to raise awareness and help patients and caregivers better navigate their journey

2018-2020 FDA Approvals Explode!

2018

- Enzalutamide FDA-approved for nmCRPC
- AR-V7 blood test available
- Germline genetic testing added to NCCN guidelines
- Abiraterone FDA-approved for mHSPC
- Apalutamide FDA-approved for nmCRPC


2019

- Darolutamide FDA-approved for nmCRPC
- Prostate EBRT+ADT standard of care for low-vol. mHSPC
- Apalutamide, enzalutamide FDA-approved for mHSPC

2020

- Olaparib, rucaparib FDA-approved for mCRPC
- ⁶⁸Ga - PSMA-11 PET imaging FDA-approved*

* Anticipated approval



Early Investment Hits the Jackpot

Immunotherapy FDA-Approved for Prostate Cancer



In May 2020, the FDA approved 2 drugs, rucaparib and olaparib, for prostate cancer treatment. These milestone achievements can be directly traced to research funded by the Prostate Cancer Foundation (PCF).

Rucaparib and olaparib are **PARP inhibitors**, a new class of therapies that are used to treat breast and ovarian cancer with *BRCA1* or *BRCA2* gene mutations. *BRCA1* and *BRCA2* are critical “DNA repair” genes, which mend broken DNA. In order to survive, cancer cells with mutations in *BRCA1* or *BRCA2* become dependent on an alternate DNA repair protein – PARP. This Achilles’ heel causes *BRCA1/2*-mutant cancer cells to be sensitive to PARP inhibitors.

The *BRCA1/2* mutant genes were first discovered in association with increased risk of breast and ovarian cancer in women; Angelina Jolie publicly shared her story of undergoing prophylactic surgery in 2013. However, PCF-funded studies demonstrated that *BRCA1/2* and PARP are also important in prostate cancer.

A team funded by a 2012 Movember-PCF Challenge Award and led by Dr. Karen Knudsen of Thomas Jefferson University provided early preclinical evidence that PARP is important in prostate cancer and that PARP inhibitors may have promise as treatments.

In 2015, the PCF International Prostate Cancer Dream Team, led by Dr. Arul Chinnaiyan, of the University of Michigan, and Dr. Charles Sawyers, of Memorial Sloan Kettering Cancer Center (MSKCC) demonstrated that up to a quarter of metastatic castration-resistant prostate cancers (mCRPC) have mutations in *BRCA1*, *BRCA2*, or other related DNA repair genes. In about half of men with *BRCA2* and *BRCA1* mutations, the mutations were inherited (see box next page).

The PCF Dream Team, led by Dr. Johann de Bono of the Institute of Cancer Research and Royal Marsden NHS Foundation Trust, initiated a Phase II clinical trial, which demonstrated that olaparib was an effective precision medicine treatment in some prostate cancer patients, particularly those with DNA repair gene mutations.

These findings inspired a race among several pharmaceutical companies to test their PARP inhibitors in prostate cancer clinical trials – 2 of which have been completed and are now under FDA review.

The randomized Phase III PROfound trial, led by Dr. de Bono and PCF-funded investigator Dr. Maha Hussain of Northwestern University Lurie Cancer Center, tested olaparib versus physician's choice of abiraterone or enzalutamide in mCRPC patients with DNA repair gene mutations who previously progressed on abiraterone or enzalutamide. The Phase II TRITON2 trial, led by 2015 David H. Koch-PCF Young Investigator Dr. Wassim Abida, of MSKCC, tested rucaparib in mCRPC patients with DNA repair gene mutations who had previously progressed on androgen receptor-directed therapy and chemotherapy.

Both trials demonstrated that PARP inhibitors are effective in mCRPC patients with mutations in *BRCA1/2* and several other DNA repair genes. However, it is not yet clear which DNA repair gene mutations beyond *BRCA2* indicate sensitivity to PARP inhibitors. *BRCA2* is the most commonly mutated DNA repair gene in mCRPC, present in approximately 8%-12% of patients.

Other PARP inhibitors currently in Phase III prostate cancer clinical trials include talazoparib and niraparib. Trials are also testing PARP inhibitors in all prostate cancer patients (regardless of DNA repair gene mutations) and in combination with other treatments.

The Prostate Cancer Foundation is proud to have funded the foundational studies that have delivered these 2 new precision medicine treatments for advanced prostate cancer.

PCF-funded studies have demonstrated that approximately 12% of men with metastatic prostate cancer have inherited mutations in DNA repair genes (most frequently in *BRCA2*) which likely caused their cancer. National Comprehensive Cancer Network (NCCN) guidelines now recommend that all men with high risk, regional, or metastatic prostate cancer undergo genetic testing for inherited mutations in *BRCA1/2* and related genes. Men found to be carriers may be not only be candidates for **PARP inhibitor** treatment, but this is also critical information for their families. Mutations in these genes are associated with increased risk for ovarian, breast, prostate, pancreatic, and potentially other cancers. Both male and female family members of carriers are highly encouraged to talk with their physicians about genetic counseling and their own cancer risk and recourse.

PCF Fundraising Community

Men and Women Across the Country are Helping Realize PCF's Mission in their Local Communities

Caregivers, survivors, family, friends, and fighters are joining together with one focus: eradicating prostate cancer. Together, PCF community members have raised more than \$2 million for prostate cancer research through a variety of local events and activities.

One observation we often hear from families who have been affected by cancer is “I feel powerless against this disease. What can I do to help?” PCF community members are leading the way, showing that anyone and everyone can make a difference in the fight against cancer. Fundraising for PCF helps bring awareness to each of our social circles, and PCF provides easy-to-use tools to activate your network in support of prostate cancer research.

Please visit pcf.org/fundraise today to learn more and join our community.

Stephen Tendrich Leads the Pink Nail Society



Stephen Tendrich was working as a bartender on Fire Island when he received a call from his father, Donald. Although he had been battling prostate cancer for years, this was the first time Donald decided to admit to Stephen that his surgery had made him feel less like a man. Stephen knew he had to do something about it. “I decided to paint my nail pink and show him, ‘Hey Dad, I’m still a man with nail polish!’” Stephen chose pink because it is a color that men are not typically comfortable with. Similar to talking about prostate cancer,

he saw it as a challenge for men to step outside their comfort zone. Stephen has since built a vibrant community through the Pink Nail Society and raised over \$15,000 for PCF’s mission by hosting local events, including an 80s Prom Night with over 200 attendees. Today, Donald has no detectable cancer. But Stephen has no plans to slow down – he is continuing to raise awareness and empathy for prostate cancer in the LGBTQ community of South Florida, and to accelerate PCF’s science through his outstanding fundraising.



The Updegraves Tackle the AT

What can you accomplish when you set your mind to it? For Dave Updegrave and his sons, Ben, Luke and Cale, the answer is “quite a lot”! These 4 fearless men from Pennsylvania set out to through-hike the Appalachian Trail from Georgia to Maine, conquering 2,200 miles on foot. They wanted “to honor our many friends that have battled and are battling” prostate cancer, and raised over \$3,400 for PCF.



Tyler Runs for his Dad

How do you show support for someone impacted by prostate cancer? How can you honor their experience and “do something about it”? For Tyler Holden, the answer came in the form of long-distance running. He took on the Cape Cod Half-Marathon, running 13+ miles and raising over \$1,800 in honor of his dad.

Becky Brings Awareness and Action to Chicago

Kevin Wegner was a beloved father and friend. When he passed away from prostate cancer he was sorely missed. To honor his memory, his daughter, Becky, organized her first ever fundraising event, *The End of an Era*, gathering over 200 friends and family members for a fun Roaring 20s-themed event in Chicago that raised nearly \$10,000 to accelerate the science to eradicate prostate cancer.



***It takes more than one person to end prostate cancer.
It takes a community. Together, we are making a difference!***

Renowned Actor Harry Lennix Teams With PCF for National Minority Health Month


In 2019, Harry Lennix, star of the NBC series, “The Blacklist,” joined PCF as a celebrity ambassador. Harry kicked off his work with a PCF public service announcement, filmed on the set in the FBI Counterterrorism Division’s office, where Lennix plays Assistant Director Harold Cooper.

Thanks to the generosity of Comcast NBCUniversal and PCF Board member Neal Rodin, the PSA had over 9 million viewings across all 50 states.



“If we give a damn about the people that we love, then we have to be here for them. And if by going to get a test once a year, get our blood drawn, if that can help – by all means, we have an obligation to do it, and it need not be feared.”

— Harry Lennix




The NBA Doubles Down on Assisting Men With Prostate Cancer

African American men are 75% more likely to get prostate cancer and over twice as likely to die from it. February 2020 launched the second annual Black History Month Assist Challenge, an initiative focused on raising awareness of disparities in prostate cancer while raising funds to support life-saving research.

In 2019, the Atlanta Hawks were the first team in the NBA to partner with PCF. This year, the Brooklyn Nets, Chicago Bulls, Detroit Pistons, Indiana Pacers and Philadelphia 76ers joined the returning Hawks to create an all-star team dedicated to educating thousands of sports fans.

Throughout February, teams donated to PCF through a variety of methods, such as \$250 for every assist, \$50 for every field goal, and 50/50 raffle earnings. Proceeds will be added to the over \$10 million already committed by PCF to research the African-American prostate cancer disparity and provide tests and treatments for better health equity.

With more teams bringing this issue to center court, life-saving information about risks and screening reached more than 800,000 people, including fans at All-Star weekend. Thanks to these 6 teams, men of all ethnicities were encouraged to know their risk and get appropriately screened.




The Atlanta Hawks, along with their official health partner, Emory Healthcare, present a check to PCF for the 2nd Annual Black History Month Assist Challenge at their February 28, 2020 game. Pictured, from left to right: Hawks cheerleader Chika Takai, PCF Young Investigator Dr. Haydn Kissick, PCF President and CEO Dr. Jonathan Simons, PCF Board Member Clark Howard, Atlanta Hawks Foundation Executive Director David Lee, Atlanta Hawks Owner Tony Ressler, PCF-funded researcher and Urology Service Chief for Emory Healthcare Dr. Martin Sanda, Medical Director of Radiation Oncology at Emory University Hospital Midtown Dr. Karen Godette, prostate cancer survivor Hugh Smith, and Atlanta Hawks cheerleader Jada Adaj



Dr. Joshua Meeks, Principal Investigator at The Robert Frederick Smith Precision Oncology Center of Excellence, serves as the ball presenter at the Chicago Bulls home game held on February 22, 2020, in recognition of his efforts in prostate cancer research

Finding Prostate Cancer Earlier... and (Much) Earlier



Before and after treatment: PSMA-based technologies have powerful potential to improve both imaging and therapy. Red lesions are prostate cancer and numbers in black represent PSA before and after treatment.

A highly sensitive new prostate cancer scan: PSMA PET

In 2020, a highly sensitive new imaging scan for prostate cancer may be FDA-approved: PSMA PET. PSMA PET is more sensitive than all standard prostate cancer imaging options, including CT, bone scans, MRI, and ¹⁸F-fluciclovine (Axumin) PET.

PSMA PET scans will enable earlier detection of metastatic disease, which is particularly relevant in patients newly diagnosed with high-risk prostate cancer, and in patients who are experiencing a rising PSA after surgery or radiation. Clinicians are testing whether using PSMA PET to direct radiation therapy in patients who have recurrent disease in the pelvis, or just a few metastases, will improve outcomes.

The PSMA PET imaging agent currently under FDA review is ⁶⁸Ga-PSMA-11, based on studies led by PCF-funded investigators Dr. Thomas Hope at the University of California, San Francisco, and Dr. Johannes Czernin and Dr. Jeremie Calais at the University of California, Los Angeles. A second PSMA PET imaging agent, ¹⁸F-DCFPyL, which was developed under a PCF Pilot Award, will be considered by the FDA in 2021. Several other PSMA PET agents are in various stages of clinical development.



Thomas Hope, MD
University of California, San Francisco
2017 Jonathan Kovler-PCF Young Investigator Award;
2018 PCF VALor Challenge Award



Johannes Czernin, MD
University of California, Los Angeles
2017 Stein Erik Hagen-PCF Challenge Award;
2019 Janssen-PCF Challenge Award



Jeremie Calais, MD
University of California, Los Angeles
2019 Janssen-PCF Challenge Award
Young Investigator

The first global Hagen Family Center of Excellence for prostate cancer theranostics

“Theranostics” – aka therapy + diagnostics, is a promising new precision medicine approach in which the same cancer protein is targeted for both cancer imaging and treatment. Ideally, the imaging is used to identify patients who will receive the treatment. In prostate cancer, PSMA is the most advanced example of this: PSMA PET imaging may soon be FDA-approved, and many PSMA-targeted treatments are being tested in clinical trials.

Enabled by a \$5 million gift from the Hagen family, in 2019 PCF established the Australian Prostate Cancer Theranostics and Imaging Center of Excellence (ProSTIC) at the Peter MacCallum Cancer Centre in Melbourne, Australia. Led by Professor Michael Hofman, MBBS, this Centre will be a global leader in conducting clinical trials and cutting-edge research on new theranostic approaches in prostate cancer and in educating clinicians on the optimal use of these sophisticated new imaging agents and treatments in patients.



The Peter MacCallum Cancer Centre in Melbourne, Australia

Extraordinary Care for Veterans

PCF's Veterans Health Initiative, Established in 2016, is Committed to Investing \$50 Million to Deliver Innovative, Cutting-Edge Prostate Cancer Care to Veterans



Dr. Julie Graff continues work on a Movember Foundation–PCF VALor Challenge Award investigating an immunotherapy that impedes the progression of life-threatening prostate cancer. Here, Dr. Graff meets with Vietnam veteran David Seidl, a successful participant in clinical research. (Photo by Aaron Bieleck)

Over the last year, the Prostate Cancer Foundation (PCF) notably expanded our Center of Excellence (COE) Network in partnership with the Department of Veterans Affairs (VA) through the generosity of several philanthropic donors who are united in the goal of providing best-in-class prostate cancer care to veterans.



August 13, 2019 – Stephen J. Cloobek receives a white coat from Vietnam-era veteran Chris Seelye for Mr. Cloobek's transformational gift advancing best-in-class care for our nation's heroes. Also shown is the multidisciplinary team at the Stephen J. Cloobek Precision Oncology Center of Excellence at the VA Puget Sound.


Four new COEs have joined our dedicated network of centers executing the ambitious mission of delivering cutting-edge precision treatments to improve the lives of U.S. veterans with prostate cancer. With the addition of the new centers, PCF has established 10 COEs to date, collaborating in a network called **Precision Oncology Program Cancer of the Prostate (POPCaP Network)**.

More than 15,000 men in the Veterans Health Administration (VHA) are newly diagnosed with

prostate cancer, and an estimated 500,000 veterans are battling prostate cancer in the VA.

The PCF has also dedicated funding to the research of numerous VA physician scientists. The platform curated by the PCF and VA is being used to build centers of excellence for several other forms of cancer and life-threatening illness including COVID-19.

“We are proud to be in partnership with the VA to deliver exceptional treatment options to our Nation’s veterans and we want each and every one to know that these Centers of Excellence exist and how to access them,” said Jonathan W. Simons, MD, PCF’s president and CEO. “No veteran should be left behind when a medical breakthrough comes to the clinic. It is our duty to ensure every veteran receives the very best care, and access to new precision treatments.”



Dr. Bruce Montgomery, National POPCaP co-chair and founder, meets with Navy veteran Allen Petchnick, whose prostate cancer has been effectively treated to date with targeted therapy at the Stephen J. Cloobek Precision Oncology Center of Excellence (Photo by Christopher Pacheco)

To learn more about Mr. Petchnick’s story, read more by Mike Richman in the VA publication *Research Currents*:
www.research.va.gov/currents/1119-VA-and-Prostate-Cancer-Foundation-look-for-aggressive-prostate-cancer.cfm



June 10, 2019 – Fellow University of Pennsylvania alumni and philanthropists Marc and Mindy Utay (Utay Family Foundation) and PCF emeritus board member Andy J. Astrachan (AJA Charitable Foundation) join medical oncologists, molecular biologists, clinical geneticists, and early-career scientists supported through their visionary philanthropic support for the Jonathan and Plum Simons Precision Oncology Center of Excellence at the Corporal Michael J. Crescenzo VA Medical Center (Photo by Philadelphia VA Medical Center)

Leveraging Relationships and Passion into New Research Dollars

2019 Special Events



Left to right: Pro tennis player Murphy Jensen in action on the court in Palm Beach, FL; One of the Indian Wells Pro-Am champions with PCF Pro-Am Tennis Program ambassador Bonnie Pfeifer Evans and tennis pro Lester Cook; Mixed doubles tennis action in the Hamptons

PCF's special events continue to be a platform for some of our most successful fundraising efforts. Without having national affiliate chapters, PCF has established events in key cities throughout each year to meet and share our critical work. These events provide unique opportunities to introduce the work of PCF, interact with our leadership team, meet our PCF-funded researchers, and raise awareness within those communities. The events have been instrumental in fostering new relationships and deepening existing ones to fund our most innovative life-extending research programs.

For over 20 years, PCF's pro-am tennis tournaments have seen hundreds of professional and amateur tennis players take to the courts and brought thousands of weekend attendees to join in our fight against prostate cancer. 2019 was another stellar year that provided exciting and unique experiences for players and guests alike. In February, we kicked off the season in Palm Beach, Florida at The Breakers, followed by the Indian Wells, California tournament played on site during the BNP Paribas Open at the Indian Wells Tennis Garden in March. The Hamptons, New York tournament rounded out the season in August. The Hamptons weekend has continued to expand and is now recognized as one of the top 5 annual events in the Hamptons. It now includes tennis on private courts, a series of robust dialogues on major topics of interest, and culminates with a gala party at the Parrish Art Museum. This year included a special performance by award-winning artist, Bryan Adams.

The tennis tournaments in 2019 raised over \$4.6 million, including \$2 million in special PCF awards.

The year concluded with our annual celebratory New York Dinner at the legendary restaurant DANIEL. With a specially-prepared menu by chef Daniel Boulud and limited to 130 people, the dinner is a highly anticipated event that provides a more intimate setting to highlight the accomplishments of our Global Research Enterprise. This year included a special performance by master mentalist, Lior Suchard, and concluded with an electrifying performance from Grammy and Oscar award-winning artist, Jamie Foxx, that brought everyone to their feet. With a clear focus on supporting new scientific programs, the evening brought in more than \$4.2 million, including \$1,125,000 for 5 new PCF Young Investigator Awards and \$1,850,000 for 4 new PCF Team Science Challenge Awards.



Eric Davidson, a 20-year veteran of the PCF tennis program, gets into the swing of things at the Hamptons tournament



Multi-award-winning artist Bryan Adams surprised guests with a special performance at the Hamptons Gala Dinner



2018 Nobel Prize recipient and early PCF-supported researcher Dr. Jim Allison joins PCF Chairman Mike Milken on stage in the Hamptons



Generous donors at PCF's 2019 New York Dinner at DANIEL



Master mentalist Lior Suchard delivers the right message at the DANIEL Dinner



Multi-talented entertainer Jamie Foxx, singer-actress Katherine McPhee, Chairman Mike Milken, and David Foster join for a very memorable evening at the DANIEL Dinner



MOVEMBER®

ACCELERATING SCIENCE TOGETHER

Since 2007, the Movember Foundation has been a definitive leader in accelerating prostate cancer research. Through its annual mustache- and awareness-growing fundraising activities and other key events, the organization has donated over \$58 million to the Prostate Cancer Foundation in support of 74 research awards in the U.S., Canada, and Great Britain. We are honored to continue the work of this incredible partnership which has led to life-prolonging and life-improving oncology developments for patients in need.

Thanks to Movember funding:

- ▶ Two new precision medicine treatments have been discovered for patients who have DNA repair gene mutations in their tumor, and these treatments will likely soon be approved by the FDA
- ▶ The discovery that inherited DNA repair gene mutations increase risk for prostate, breast, ovarian, and other cancers has led to precision genetic counseling for family members of men with prostate cancer
- ▶ More than 70 clinical trials testing new prostate cancer treatments and imaging technologies have been initiated



Movember Foundation Global Director of Biomedical Research Programs, Mark Buzzza (fifth from left), and Executive Director of Programs, Paul Villanti (far right), pose with recipients of the 2019 Movember Foundation-PCF Team Science Challenge Awards at PCF's 26th Annual Scientific Retreat in Carlsbad, CA

- ▶ A more sensitive new imaging technology, PSMA-PET, has been developed for visualizing prostate cancer recurrences earlier
- ▶ Many new drugs have entered the R+D pipeline for treatment-resistant prostate cancer
- ▶ Biomarkers, including AR-V7, have been discovered that help doctors to choose the most appropriate treatments for patients
- ▶ Blood tests are being developed to analyze tumor mutations so that patients can avoid invasive biopsies of metastatic disease

PCF is profoundly grateful to Movember for this life-saving partnership.



THE JERRY II

JERRY WEINTRAUB
CELEBRITY PRO-AM GOLF TOURNAMENT

Golf for Good: Honoring a Hollywood Legend

When the Entertainment and Sports worlds unite around a great cause like the Prostate Cancer Foundation, it translates into greater fundraising for our research programs. Such is the case for a core group of donors supporting our efforts in honor of an icon in the entertainment world: Jerry Weintraub.




A fab four teeing it up (from L-R): Actor Kevin Rahm, Robin Nordhoff, PGA Tour Pro Mike Grob, and PCF Board member Henry Nordhoff

Jerry had a passion for all of humanity: in both life and in his films, he always found the

goodness in our hearts to do the right thing. The Jerry Weintraub Celebrity Pro-Am Golf Tournament merges Hollywood and Professional Golf, with the people who knew and loved Jerry.

Hosted for the second time at the impeccable and exclusive Madison Club in La Quinta, CA, The Jerry II brought together



Son of the late, great Jerry Weintraub and Tournament Host, Michael Weintraub in action on the course




Actor John O'Hurley not only conducted the event auction, but provided comic relief on and off the course




A host of Jerry's friends enjoying the Gala (from L-R): Alfonso Ribeiro, Bill Smitrovich, Daren Lasky, Cathy Warburton, Patrick Warburton, Kevin Rahm, Richard Kind, Paula Trickey, and Leslie Foumberg

some of Weintraub's closest friends for a day of first-rate golf, fundraising, and good times. We extend special thanks to all of our sponsors, including Casamigos, Indigo Auto Group, and the Weintraub Family Foundation, as well as our friends and donor-partners: CBS All Access, Garmany Golf, Under Armour, and Ritmo Mundo, who produced our beautiful limited-edition custom watches for our golfers. In total, the event raised more than half a million dollars for PCF research and partnering charities.

The Dickson Family and



During PCF's 2019 Home Run Challenge Tour, the Dickson Family joined PCF Founder and Chairman Mike Milken for the PCF-Seattle Mariners Home Run Challenge game. To honor the memory of their beloved daughter, Andy Dickson's employer, the Odyssey Group, partnered with PCF to establish the Kelsey Dickson Team Science Courage Research Award at the Fred Hutchison Cancer Center. Project leads Drs. Peter Nelson and Paul Nghiem are leading a study encompassing the overlap of Merkle Cell Carcinoma and small cell prostate cancer, advancing us all that much closer to a cure across multiple forms of cancer.



MLB All-Star Gerrit Cole met with Team PCF prior to the HRC-Houston Astros Game.

PCF Team Up for a Cure!



Baseball legend Steve Garvey joined the HRC Crew to promote prostate cancer awareness in San Diego.



Dennis and Janet Barnett continued to support PCF through the RNDC Sponsorship of HRC.

Sheffler Strong

When Pat Sheffler's son needed to sell some more insurance to hit his bonus, Pat did what any good dad would: he bought more insurance from him. Before Brandon Sheffler could issue the new policy, his dad needed to undergo a routine physical; no problem, because Pat Sheffler, at age 53, was a multi-sport athlete – the kind of guy who runs marathons AND plays basketball 2 hours per day.

But the life insurance company called Pat with some concerning news – his PSA was 37. Brandon had already done some research and was ready with, “Don’t worry, Dad, it’s probably just a false positive.” Not so. Pat was diagnosed with Stage 3 prostate cancer.

“The biggest thing in my entire world is my family,” says Pat, “Very first thing I thought was, ‘My poor son.’ Your mind goes a million directions. After I calmed down, I remember thinking, ‘I am not missing my daughter’s graduation, no matter what.’”

Pat had stage 3 prostate cancer. In stages 1 or 2, PSA has started to rise, but the cancerous cells are confined to the prostate. In stage 4, the prostate cancer cells have traveled to other parts of the body, most commonly lymph nodes and bones. But in stage 3, the tumor has often started to bulge outside the prostate without (yet) any evidence of distant metastasis. 50%-80% of men who undergo surgery for stage 3 prostate cancer see their PSA rise again within 10 years.

Pat, 53 at the time of diagnosis, did his own extensive research on treatment, going as far as UCLA, USC, and the Mayo Clinic, only to determine that the best doctor to do his surgery was urologist Dr. Christopher Kane, right in his own backyard at UCSD. Furthermore, as luck would have it, there was a PCF-funded clinical trial, looking for high-risk patients with just his profile.

The trial, led at UCSD by PCF-researcher Dr. Rana McKay, in collaboration with Dana-Farber Cancer Institute, grew out of a 2014 PCF Challenge Award with study Principal Investigator Dr. Mary Ellen Taplin. It asks the question: **“Can we cure more patients if we apply more potent hormonal therapies at the early stages of disease?”**

“Before I even had the surgery, they put me on prednisone, Lupron, apalutamide and abiraterone.” Because Pat had a hormone-sensitive prostate cancer, the drugs he was on were designed to decrease androgens and block their activity. “I got tested every month before surgery and watched my PSA numbers drop – 34, 27, 21, 10, 4, 2, 0.2.” After surgery, Pat participated in the second part of the trial to test whether another year of hormone therapy would improve outcomes.

Pat had the surgery on November 5, 2018. The day before, he walked 5 miles with a friend who had been diagnosed with breast cancer at a similar time as he was diagnosed with prostate cancer. “She kept saying, ‘Why are you here, you have surgery tomorrow?’ and I kept saying, ‘I’m here because I don’t have surgery until tomorrow.’”



Left to right: Pat Sheffler, son Brandon, daughter Ashlen, and wife Caren the day before treatment ended

Pat has done 7 marathons and multiple Spartan-type races (some with his whole family). He's played in the same community softball league for 40 years – in the 80s, with his dad, and now with his sons. He typically plays basketball 2 hours a day. He's in about as good shape as you can be for a guy who's 55.

“When I had the surgery, the doctor made a point of telling me how healthy I am on the inside. I played basketball before and after treatment – 13 hours a week, never missed a week. I eat whole foods and I'm a super positive person, no matter what. I think that matters. Life is what you make of it. **My family never got depressed, because I never got depressed. Positive vibes is my thing.**”

A few months after his diagnosis, Pat showed up to a softball game... only to find his son Brandon in a t-shirt that said “Positive Vibes” on the front and “Sheffler Strong” on the back. Then his other son, Tristen, showed up with the same shirt on. “I want one, why didn't you get me one?” Pat said. And then his mom showed up with one. And his wife. And his friends and his nephew and another 20 people showed up with the same shirt. As Pat tells it, “I wear my heart on my sleeve, so it impacted me in a big way. Later after practice, we went to a local pizza place. ‘Why don't you open Facebook?’ my daughter Ashlen said.” There, Pat found that his wife and daughter had orchestrated a secret Facebook group, where 100s of people around the world had all taken pictures of themselves in the same shirt.

The clinical trial and positive vibes finally paid off. A year after surgery, Pat went off the drug protocol. Two months later and still off the trial meds, his PSA was undetectable. Furthermore, his testosterone was rising back to normal. “It is a highlight of my profession,” says Dr. McKay, “This is how we get the next best therapies out there for patients. **These are the moments and breakthroughs we look for.** I always say, Remission + Time = Cure. My hope for Pat is that he's cured – that he can go on just being an amazing dad, husband, and advocate for prostate cancer awareness.”

“What I take from this, from a selfish perspective, is that I'm proud that my life leading up to this was authentic. I've always been a positive, outgoing, happy person and that's the truth. You would never know I was diagnosed with anything. We manifest our own health by positive energy, and a positive mindset is a big part of that.”



Pat Sheffler, surrounded by friends, family, and Positive Vibes

Elevating Leadership for Women in Science



2019 PCF Women in Science Forum organizing committee members (from left): Lorelei Mucci, MPH, ScD, Harvard T.H. Chan School of Public Health; Amina Zoubeidi, PhD, Vancouver Prostate Centre; Himisha Beltran, MD, Harvard Dana-Farber Cancer Institute; Karen Knudsen, PhD, Thomas Jefferson University; and Andrea Miyahira, PhD, PCF Director of Global Research and Scientific Communications

For the fourth year in a row, at the 2019 PCF Scientific Retreat, PCF acknowledged the amazing contributions that women have made in the field of science and medicine, specifically in prostate cancer research with the Annual PCF Women in Science Forum.

Before PCF began to encourage prostate cancer researchers by funding their early careers, the numbers of women in the field were few. Through our Young Investigator Awards and Team Science Challenge Awards programs, PCF has helped to increase the number of women who are building a long-term career in prostate cancer research.

Dr. Andrea Miyahira – who has been instrumental in leading the program – described the benefits. “It has been so rewarding to be a part of this amazing group of scientists, clinicians, and leaders in the field. As PCF’s Director of Global Research, I have seen many young women investigators grow their skills through mentorship over the years.”

In 2019, in recognition of career issues unique to women, 4 female PCF-funded investigators, Drs. Karen Knudsen, PhD (Thomas Jefferson University), Lorelei Mucci, ScD (Harvard School of Public Health), Himisha Beltran, MD (Weill Cornell Medicine), and Amina Zoubeidi, MSc, PhD, hosted the PCF Women in Science Forum, to which all female (and any interested male) attendees are invited to attend. The goals of the Forum are to create a network of PCF-funded women scientists, to team-build through discussion and social events, to ensure a strong pipeline of female prostate cancer researchers and clinicians, and to identify opportunities for further training, mentoring, and synergy of a stellar network of female prostate cancer researchers and clinicians.

PCF Catalyzes the Development of a Polygenic Test for African American Men at Highest Risk


Studies of cancer in twins have revealed that 57% of all prostate cancer runs in families; one might say that this makes prostate cancer the most “family inherited” form of human cancer. For the last 20 years, the Prostate Cancer Foundation has been funding the detective work to figure out which single genes – out of 22,000 in the human genome – might be responsible for the most aggressive prostate cancers (for example, the *BRCA1* and *BRCA2* genes). Now, PCF-funded researcher Chris Haiman has made a significant finding,

discovering that often it is not a single gene, but rather dangerous combinations of genes, that together severely increase lifetime risk for prostate cancer and run in families.

Here’s another way to think about this fascinating result. There are 100s of genes *related* to prostate cancer that you may have inherited from your parents. We now know there are several *combinations* of genes – think of it like a hand of cards you are dealt when you are born – that can confer significantly higher risk for aggressive disease. Haiman and his global research team also discovered that African American men are more likely to have been dealt a particularly bad hand: some of the worst combinations of genes for prostate cancer risk are unique to men of West African descent.

PCF has also spent many years trying to unravel the complexities of health disparity in prostate cancer for African American men, who are 76% more likely to be diagnosed and more than twice as likely to die from the disease. Using a comprehensive analysis of all the genetic risk data around prostate cancer for men of different ethnicities, including those of African descent, Haiman hopes to be able to create a test to assess a man’s lifetime risk of developing prostate cancer. This test has great potential, allowing doctors to identify men who may have up to 4 times higher risk of getting prostate cancer than the average guy; if we can get them tested and tracked earlier, we can save lives.

Because prostate cancer is 99% treatable if detected early, this “precision screening” test could be a game-changer for men’s health, as well as a key factor in reducing the overall disparity in death rate for men of African descent. More R+D is needed to optimize this innovative new test. As a next step, Haiman and team will make sure that cutoffs for risk groups are as accurate as possible, in the same way that the output of your cholesterol test places you in a high, medium, or low risk category for cardiovascular disease.



Drs. Chris Haiman (left) and John Carpten (right) of USC Keck School of Medicine with former L.A. Laker Michael Cooper

Supporting Cures

There are millions of men currently living with prostate cancer. To support the urgent need for better treatments and cures, the Prostate Cancer Foundation offers individuals and charitable foundations various options for becoming involved and supporting crucial research.

Donations

Please mail your check to:

Prostate Cancer Foundation
1250 Fourth Street
Santa Monica, CA 90401

To make an online contribution, please visit our website
www.pcf.org

Blue Ribbon Society

- ▶ Join our elite group of loyal supporters devoted to fostering breakthrough science with a monthly recurring contribution

Memorial or Tribute Gifts

- ▶ Honor the memory of a loved one or celebrate the accomplishments of a friend or family member by helping others with a tribute gift
- ▶ If desired, PCF can also set up a special webpage to honor your loved one and collect donations

Matching Gifts


- ▶ If your company offers an Employee Matching Gifts program, you can make your hard-earned dollars go twice as far with a matching gift to PCF

Other Gift Suggestions

- ▶ Gifts of stock
- ▶ Support PCF in your estate planning
- ▶ Name PCF as a beneficiary of your IRA or life insurance policy
- ▶ Federal employees and retirees participating in the Combined Federal Campaign (CFC) can designate PCF as a beneficiary

For more information, visit:

www.pcf.org/donate



PCF Research Awards

PCF advances its research priorities through three competitive award types:

Team Science Challenge Awards

(\$1,000,000 and above for 2- to 5-year programs)

Team Science Challenge Awards make large investments in multi-year projects that have a high potential for delivering new treatments and diagnostics.

Creativity Awards

(\$300,000 for 2-year programs)

Creativity Awards support the development of high-risk, high-reward ideas from established senior scientists.

Young Investigator Awards

(\$225,000 for 3-year career investment)

The Young Investigator Awards offer early-career and project support for the ideas of exceptional investigators (generally 35 years old and younger), who are committing their lives to the field of prostate cancer. Their institutions match the award dollar-for-dollar.

PCF-VA Center of Excellence Awards

In 2016, the PCF committed to invest \$50 million over 5 years to advance precision medicine for America's veterans. Together, PCF and the U.S. Veterans Administration are building a network of Precision Oncology Centers of Excellence focused on expanding access to genomic sequencing and innovative clinical research.

2019 Donor Roll

The support of our generous donors makes all that we do at PCF possible. This honor roll acknowledges actual gifts of \$1,000 or more, exclusive of pledges, made to PCF during calendar year 2019. We thank you, our friends and supporters, for your continued commitment to PCF's mission.

\$1,000,000-\$4,999,999

Stein Erik Hagen Allmenntyttige
Stiftelse
Janssen Research and Development,
LLC
The John and Daria Barry Foundation
The Michael and Lori Milken Family
Foundation
Movember Foundation
Odyssey Group Foundation
Ruvo Family Foundation
Lawrence R. Souza Revocable Living
Trust

\$500,000-\$999,999

AJA Charitable Fund
Anonymous
The John Black Charitable Foundation
Brewers Community Foundation, Inc.
Credit Suisse Securities (USA) LLC
Edelman Family Foundation
Edward P. Evans Foundation
The David Geffen Foundation
Heritage Medical Research Institute
Sun Pharmaceuticals Industries
Teach A Man To Fish Foundation

\$250,000-\$499,999

Anonymous
Bayer HealthCare Pharmaceuticals,
Inc.
Robert and Cynthia Citrone
Facebook, Inc.
Genzyme Corporation
J. C. Kennedy Foundation, Inc.
Herb and Natalie Kohler
Fred B. Luddy Family Foundation
Motsepe Foundation
Estate of Calvin Patterson
Pfizer, Inc.
Marlene M. Ross Revocable Trust
The Morris and Alma Schapiro Fund
Mr. Michael S. Smith and Mrs.
Elizabeth A. Smith
Utay Family Foundation

\$150,000-\$249,999

Atlanta Hawks Foundation, Inc.
Reina and Emilio Bassini
Dr. Michael M. Berns and Tricia Berns
Susan and Jim Blair
Todd Boehly
Clovis Oncology, Inc.
The Durden Foundation, Inc. / Mr.
Michael Durden / Mrs. Earl Durden
David and Judith Fleischer
Shmuel Meitar

Mr. Anthony D. Minella and Mrs. Sage
Minella
Mizel Family Foundations
Mr. Thomas S. Smith and Ms. Caroline
Fitzgibbons
Thomas H. Lee and Ann Tenenbaum
Mr. Igor Tulchinsky
Mr. Larry J. Winget
Yurman Family Foundation, Inc.

\$100,000-\$149,999

Joseph and Annette Allen
Amgen, Inc.
AstraZeneca
Authentic Brands Group, LLC
Aven Foundation
Bill and Ann Bresnan Foundation, Inc.
Bristol-Myers Squibb Company
The Cleveland Clinic Foundation
Coller Capital
Mr. Paul Coulson
Neil and Sandra DeFeo Family
Foundation
Mr. Louis Dorfman
Eldridge Business Services, LLC
Fuego Box LLC
Graziadio Wellness Foundation
Michelle and Joseph Jacobs
Jordan Industries, Inc.
Eric A. Klein, M.D.
Mr. Gary A. Lieberman
M. C. Dean, Inc.
Major League Baseball Charities, Inc.
Merck and Co., Inc.
Minnesota Twins
Paulson Family Foundation
Republic National Distributing
Company, LLC
Cliff and Debbie Robbins and The
Robbins Family Foundation
Ms. Alice Rogoff and Mr. David M.
Rubenstein
Mark and Rosalind Shenkman
Mr. Scott Simon and Mrs. Hillary
Simon
Sun Capital Partners, Inc.
The Wagner Family Foundation
Mr. Andrew S. Weinberg

\$50,000-\$99,999

Dr. Elliot Abramowitz
Advanced Accelerator Applications
Anonymous (3)
Astellas Pharma Global Development,
Inc.
Baratta Family Fund
Douglas and Joanne Berry Charitable
Fund

Greg and Anna Brown Family Fund
Mr. Mike Burkland and Mrs. Kathy
Burkland
Arthur and Eva Byrnes
Casamigos Tequila LLC
Howard Cox
Mr. Tim Connors
CRIS Foundation
Daiichi Sankyo, Inc.
Mr. Michael DeAddio
Dendreon Corporation
Derric's Day for Prostate Cancer
Awareness
Donnini-Rudolph Family Foundation
The Eustace Foundation Trust
Eugene and Sallyann Fama
Mr. Thomas M. Finke and Mrs. Heather
Finke
Keith Frankel
Julie and Martin Franklin Family
Foundation
Peter and Laurie Grauer
Clay and Lynn Hamlin
Mr. Timothy A. Hanson and Mrs. Alida
J. Hanson
William B. Harrison Foundation
HLT Prostate Cancer Fund
William P. and Dorian S. Jordan/
William P. and Dorian S. Jordan
Foundation, Inc.
Kissick Family Foundation
Kovler Family Foundation
The Laughlin Aldisert Family Fund
Dalia and Larry Leeds/The Leeds
Family Foundation
The Frances And Craig Lindner
Foundation
The Maguire Foundation
Charles N. Mathewson Foundation
Modell's Inc.
The Donald R. Mullen Family
Foundation, Inc.
The Nerney Foundation
Progenics Pharmaceuticals, Inc.
Ressler/Gertz Family Foundation
Brian and Patricia Reynolds
Michael J. Rinaldi Jr. Revocable Trust
Riverview Flats Pty, Ltd
Daryl and Steven Roth Foundation
The San Francisco Foundation
Mr. Leonard Sands
Ms. Lucy Shostak
The Robert and Jane Toll Foundation
The Weintraub Family Foundation
Wild Dunes Men's Golf Association
Wycliffe Country Club Men's Golf
Association
Zisk Family Foundation

\$25,000-\$49,999

Anonymous
The Elias, Genevieve and Georgina
Atol Charitable Trust
The Cecile and Fred Bartman
Foundation
Candice Beaumont
Arthur Becker and Vera Wang
The Sybiel B. Berkman Foundation
Jay and Alison Bernstein
Mr. and Mrs. Seth Bernstein
Mr. Miles Boldrick
Anthony and Jamie Carr
Johnny Carson Foundation
Dick and Lisa Cashin
CBS Interactive US
Celgene Corporation
Chicago White Sox
Mr. Joe Cipriano
Robert D. Collins Fund
Mr. Jon Corn and Mrs. Dawna Corn
John R. and Kiendl Dauphinot Gordon
Fund
Mr. and Mrs. Eric K. Davidson
ECOR1 Capital, LLC
Faith, Love, Hope, Win Foundation
Ralph and Cynthia Finerman
Flanagan Family Gifting Account
Friedman-French Foundation, Inc.
Fuhrman Family Foundation
Genentech, Inc.
Mr. Gerald Gibian
GoldenTree Asset Management
Mr. Jeff Greene and Mrs. Mei Sze
Greene
John A. Griffin
Johnson & Johnson Services, Inc.
Mr. and Mrs. Steven B. Klinsky
Stephanie and Ron Kramer
Lateral Investment Management, LLC
Ms. Jane A. Lauder
Mr. Paz Littman
John and Linda MacDonald Foundation
Mr. and Mrs. Donald B. Marron
Medical Research Charities
Jerome Meislin
Mr. Michael A. Mendelson
Ted and Dani Virtue
MJR Foundation
Mr. Terry R. Montesi and Mrs. Allison
Montesi
The Moreno Family Foundation
Mr. Mark E. Nicol
Mr. Gerald E. O'Shaughnessy
Paluszek Family Foundation Inc.
Power Design, Inc.
R.S. Evans Foundation
Rance King Properties, Inc
Marc J. and Carolyn Rowan

Ronald Rubin
Mr. Arik Ruchim
Mr. Kern W. Schumacher
Mr. Mickey Shapiro
The Sinder Foundation
Mr. and Mrs. Clifford M. Sobel
Mr. William F. Springer
Lisa and Steven Tananbaum Family Foundation
Julie and Bobby Taubman
Mr. and Mrs. Roger Taylor
Mr. Michael Uhl
Barry & Teri Volpert Foundation
Mr. George H. Walker and Mrs. Nancy Walker
Mark & Nancy Weinberger Family Foundation
Mr. and Mrs. Daniel Weingeist
E. L. Wiegand Foundation
Witte Family Charitable Gift Fund
Mrs. Hsin Yue Yong
Mr. Anthony A. Yoseloff
Young's Market Company
Zamansky LLC

\$15,000-\$24,999

Mr. Craig Albert and Mrs. Darla Albert
Anonymous (2)
Brandon's Bourbon Inc.
Joel M Brown IRA Beneficiary Trust
The Steven A. and Alexandra M. Cohen Foundation, Inc.
Constellation Pharmaceuticals
Mrs. Lisa Cummins
Mr. Brendan Curran
Mr. Charles Davidson and Mrs. Theresa Davidson
David Dollinger Living Trust
Mr. and Mrs. Ralph Eads, III
Ezra AI, Inc
Mr. Marshall Ezralow
Mark Finerman
Anne K. Gilhuly
Bennett and Meg Goodman
John and Kiendl Gordon
Harpoon Therapeutics
Mr. David Herro
Hodgson Revocable Family Trust
Mr. Jerry Katell
Alice Lawrence Foundation, Inc.
Mr. Jonathan Letzler and Mrs. Brenda Letzler
Margaritaville Holdings, LLC
Mr. and Mrs. Michael Marquart
R.N. Milikowsky Family Foundation
Mr. Kammy Moalemzadeh
Mr. and Mrs. Henry L. Nordhoff
Arthur Penn
Dorothy Phillips Michaud Charitable Trust
Sandra and Lawrence Post Family Foundation
Reiter Affiliated Companies, LLC
The Harold Ripps Caritable Foundation
Bob Roberts
Richard and Phyllis Sharlin
Mark J. Simon
St. Andrews Foundation
Sam Herzberg

Mr. Richard Stone and Mrs. Lesley Stone
Wallack Family Foundation

\$10,000-\$14,999

Acquavella Family Foundation
Anonymous (3)
Eric Aroesty
Assaf Family Trust
Mr. Duncan Bagshaw and Mrs. Lisa Bagshaw
Barclays
Ron and Judy Baron
Mr. Keith Bertolino
BNP Paribas USA, Inc.
Mr. and Mrs. David C. Brown, Jr.
Calamos Advisors, LLC
Gary Charlesworth
Charlesworth FLP
Ms. Joann Chasen
Courtney and David Corleto
Mr. Jack Curtin and Mrs. Beth Curtin
Mr. Gary S. Davis and Mrs. Ellen Davis
Mr. Alex Engemann
Andrew H. Feinman
Fuente Family Foundation, Inc.
Mr. Glenn Fuhrman
Mr. James Gary and Mrs. Sylvia Gary
Mr. Michael Gismondi
Mr. Greg Gliner
Mr. Justin Gmelich
Mr. R. Stephen Hannahs
Mr. Robert F. Hogan, Jr.
Eric D & Steven D Hovde Foundation
Clark.com
Mr. David B. Humpton and Mrs. Barbara W. Humpton
Hurwitz Family Foundation
JP Morgan Chase & Co.
Chris & Mary Ellen Kanoff Family Foundation
Mr. Bradley R. Krevoy
Devi Kupsammy
Mr. Carey F. Lathrop
Heyson C. Leach
The Lefkowsky Family Foundation
Mr. and Mrs. John Lucchesi
Suzi And Scott Lustgarten Family Foundation
Mr. Howard Lutnick and Mrs. Allison Lutnick
The Bill and Jodie Mackintosh Family
Mr. Solomon Martinez
Mr. and Mrs. George A. Mealey
Robert Merrill Parker Trust
Nicholas Mitsiades, M.D., Ph.D.
Bethany and Niko Elmaleh
Mr. Edward Oakley
Joel M. Pashcow
Mrs. Hansa Patel
Mr. and Mrs. Dave Perron
The Powers Family Foundation
Estate of Michael Eugene Preston
Roman Health Ventures Inc.
San Diego Golf Course Superintendents Association
Mr. and Mrs. Jeffrey Schottenstein
William and Valerie Schwartz Family Foundation
Mr. Michael H. Scott

Shutterfly, Inc
David E. and Jacqueline S. Simon Charitable Foundation
Herbert Simon Family Fund
Skelton Family Fund
Gary Stoneburner
Mr. Peter Strelow
The Tuchman Family Foundation
UBS AG
Mr. Robin Ventura
Mr. Ron White
Mr. Andrew Whittaker and Mrs. Stephani Whittaker
Art Winkleblack

\$5,000-\$9,999

Joseph P. Adams, Jr.
Mr. Lee Adrean
Anonymous (8)
Mrs. Shari L. Aronson
Paul Baranay
Roger Barnett
Mr. Stuart Bascomb and Mrs. Phyllis Bascomb
Dr. Judy Bastedo
Mr. William P. Becker and Mrs. Debbie M. Becker
Battle at Bella Vista
Bonanza Casino
C.A.R.E (Cancer Alzheimer's Research Event)
Canoe Brook Country Club
Mr. Jared Carney and Mrs. Deirdre Wallace Carney
Mr. and Mrs. Richard Chadakoff
Mr. Howard Chai
Allen and Jill Chozen
Mr. David R. Chubon
Dauber Foundation Fund
Mr. A.W. Dieffenbach, Jr.
Mr. and Mrs. Robert J. Dunne III
Mr. Bret D'Vincent
Stephen Edelmann, Edelmann Family Foundation
Elizabeth Ventura and Stephen Eisenmann
Mr. Jonathan P. Evans
Dr. Jeffrey P. Feingold
Mr. and Mrs. George A. Mealey
Mr. Robert G. Fuller Jr.
Ms. Gayle Gaines
German Masonic Charitable Foundation
Mr. Stephen A. Gillin
Mr. Jonathan Goldstein
Mr. Julian Gordon
Mr. Joseph G. Greenberg and Mrs. Claire L. Greenberg
Mr. Mark S. Henderson
Douglas J. Hertz Family Foundation
Mr. and Mrs. Raymond Hwang
The Hwang Foundation
Ms. Julie C. Jaeger
Ms. Sheryl Kaye
Mr. Vernon Keist
Kelsey Family Charitable Fund
Memorial Sloan Kettering Cancer Center
Mr. Casey Kirkman
Mr. Thomas P. Knight

Kathleen and Kirk Knous
Stacey and Larry Kohl
Mr. Robert S. Kricheff and Mrs. Daphne A. Bowe
Mr. Philip Larman
Mr. and Mrs. Harry Lee
Mr. George Liao
The Thalia & George Liberatos Foundation
Mr. Michael Lichtenberg
Dr. Edward Loftspring
Lords Valley Country Club
Mr. John Lykouretzos and Mrs. Joella Lykouretzos
Mr. and Mrs. Paul Madura
Manowitz and Drillings Family Foundation
Mr. Steve Mark
Martin/Martin Consulting Engineers
Mr. Donald McComb and Mrs. Vickie McComb
Mr. William McDaniel
Mr. George McDowell
Mr. and Mrs. Donald A. McMullen, Jr.
Meadow Club
Mr. John Meglen
Ms. Olivia Miller
Mrs. Leslie Murphy
Miles Nadal
L. Mark Newman Family Foundation
Mr. and Mrs. Scott G. Nichols
Colleen and Tagar Olson
John Paffenbarger
Mr. Gerald L. Parsky
Mr. Ruchir Patel and Mrs. Rachel Patel
Mr. Stephen J. Pearce and Mrs. Kristine E. Pearce
PharMerica Corporation
Pink Nail Society, Inc.
Mr. and Mrs. James T. Pizzo
Quine Family Trust
Mr. Douglas Rachlin
Ms. Ramola Daswani
Rar Family Foundation
RCM Rise & Shine Memorial
Kathleen Redmond
Ms. Kathleen Lister and Mr. Jeffrey A. Reinhold
Mr. Alfonso Ribeiro
Mr. Brian Riley
Mr. Rich Saso
Ms. Kathleen Schell
Mr. Brian Selmo and Mrs. Suzanne Selmo
Sempered USA, Inc.
Mrs. Suzy Shechtman
Jonathan and Plum Simons
The Sloan Foundation
Ms. Arlene Smadja
Mr. Carl Sperber
Sweetwater Community, Inc.
Terravita Golf Club
Mr. E. Paul Tinsley
Mr. and Mrs. Michael W. Urbut
Dr. and Mrs. Andrew C. von Eschenbach
Ms. Caroline A. Walker
Mr. Andrew Weinberg
Mr. Alwin J. Wenzel
Mr. and Mrs. Harry J. Wild
William L Price Charitable Foundation

Williams, et al. v. Biotab
Nutraceuticals, Inc.
Mr. Theodore Woehrle and Mrs.
Pamela Woehrle
Terry L. Wright

\$2,500-\$4,999

IEC - Fort Worth Tarrant County
Chapter/ IEC - Dallas Chapter
AmazonSmile Foundation
Anonymous (15)
Dr. Elena Antonova
Arc International North America
Gene Armatorio Family Charitable
Fund
Mr. J. Jeffrey Assaf
Ms. Kristen Baltgalvis
Dr. Shubha Bargrovia
Mr. and Mrs. Barry M. Berish
Mr. and Mrs. Charles B. Bernicker
BGC Legs
Mr. Thomas Biermann
Mr. Antony Blinken
The Boucher Charitable Foundation
Mr. Nigel Brooks
Frank Brosens and Deenie Brosens
Foundation
Mr. Ken J. Buck and Mrs. Cathleen A.
Buck
Dr. Ben Buelow
Bussman Family Philanthropic Fund
Dr. Douglas Campbell
Mr. Gregory W. Cappelli and Mrs. Mary
Cappelli
Ms. Gina B. Carithers
Dr. Alessandra Cesano
Isan Chen, M.D.
Mr. and Mrs. James T. Clarke
Westin Columbus
Ms. Laura Cosentino
Dr. Rob Crombie
Mr. and Mrs. James L. Crothers
Ms. Donna Curtis
Elai Davicioni, Ph.D.
Mr. Tom De Weerd
Dr. Ryan Dittamore
Charles Edelstein
Mr. Donald Eilenberger
Mr. Joe Ferraro
Dr. Jason Fisherman
The Philip M. Friedmann Family
Charitable Trust
Ms. Staci Friedwald
Dr. John Friend
Mr. Simon Furie and Mrs. Lori Furie
Brooke Garden
Dr. Pat Garrison
The Gibson Family Foundation
Mr. and Mrs. Wayne Giebler
Ms. Susan Graziano
Mr. William Greene
Reverend Roosevelt Grier
Ms. Barbara Jean Helvie
Mr. and Mrs. Herbert Muther
Hernando Firefighters Benevolent
Relief Fund
Mr. and Mrs. Andrew Herz
The Hill Family Charitable Foundation
Mr. Peter Holbrook
Dr. Eric Horler

IBM Employee Services Center
Neema Jamshidi, M.D., Ph.D.
Johns Hopkins University
Mr. G. Donald Johnson
Kearney & Company
Llew Keltner, M.D., Ph.D.
Knoxville Law Enforcement Federal
Credit Union
Mr. Robert Kraft
Mr. John Lapolla, III
Dr. Ronan Le Moigne
Lift Foundation, Inc
Mr. Chris Lloyd
Stewart Manheim
Mr. and Mrs. Robert Mansfield
Mr. Kirke Marsh
Mr. Mario Masciantonio
Mr. Joseph Maurer
Mclaren Autobody Inc.
Law Office Of Joan M. Medeiros
Mr. Shawn Meyers and Mrs. Kari J.
Meyers
Mitchell S. Meyers and Jacqueline P.
Meyers Foundation
Mr. Brian Mingham
Dr. and Mrs. R. Bruce Montgomery
Angelo and Phyllis Mozilo
Network360
Mr. Kendall D. Newman
Jonathan R. Novak
Riikka Oksala
Mr. Michael O'Neill and Mrs. Jeannie
O'Neill
The Oregon Community Foundation
Palani Palaniappan
Palm-Aire Country Club at Sarasota
Mr. and Mrs. John M. Parker
David Parkinson, M.D.
Mr. William Payne
Dr. Ronald Peck
Neil Pegg
Bonnie Pfeifer Evans
Mr. Bartley Pitcock
Edward J. Primet and Lorraine E.
Primet Revocable Trust
Mr. and Mrs. William Pullia Jr.
Patricia Quintana
Mr. Jonathan Ressler
James S. Riepe Family Foundation
Mrs. Louise C. Rigg
Drs. W Scott and Karen T Robertson
Mr. Michael Rock
Mr. Bradford Roller and Ms. Laura
Pedersen
Mr. Harvey Rose
Dr. Adrian Rosebrock
Mr. and Mrs. Jay K. Rosenblatt
Mr. Mark Rubin
Edward B. Rust, Jr.
Vivek Saini
Mr. and Mrs. Leland Sandler
Mr. John Sarto
Joseph Schonhoft
Lynn Seely, M.D.
Mr. Michael Sellett
Kim Shafer
Sheffield Pharmaceuticals
Mr. Dax Shepard and Mrs. Kristen Bell
Mr. Roderick Sherwood
Mr. Gary Singer

Bryan Smith
Smithburg Family Foundation
Marilyn and Lee Snider
Ms. Geeta Solanki
Mr. Farrel Starker
Zhen Su, M.D.
David V.N. Taylor Foundation
UBS Financial Services
Mr. Donald J. Toumey
University Park Country Club
Associates
Ms. Rachel Vaizer
Peter Virsik
Mr. and Mrs. Robert E. Wade
Rick Wenstrup
Mr. Paul M. Westbrook
Mrs. Elaine Wheeler
Ms. Sharon Woolman
Mr. Jeff Yee
Mr. Robert S. Zamarripa
Mr. Atanaz Zargar
Daphna Ziman

\$1,000-\$2,499

Mrs. and Mr. Karen Adam
Stan Adler
Mr. Robert M. Agans
Mrs. Karen Akers
Lee Alan Enterprises, LLC
Mr. Louai Alassar
Mr. Jonathan Albert and Mrs. Rachel
Albert
Mr. Alfred John
All Star Tire Co., Inc.
Mr. and Mrs. David C. Allen
Mr. Laurence Allen
Alloya Corporate Federal Credit Union
Mr. Joe Alwan and Mrs. Mary Ann
Alwan
Mr. Denis J. Amato and Mrs. Janice
Amato
American Nevada Company
Mr. Roger W. Anderson and Mrs. Pat
Anderson
Anonymous (21)
Judd Apatow
Mr. Gerald W. Apel and Mrs. Kathleen
Apel
Mr. Alan Appelbaum
Mr. Kenneth Aspromonte
Astrup Family Foundation
Mr. Paul Attner and Mrs. Lucy Attner
Aux Sable Liquid Products LP
Mr. Burl V. Bachman and Mrs. Pamela
Bachman
Mr. Jeffrey Baevsky
Mr. James D. Bagwell
Mr. and Mrs. Ken Baker
Baker Botts, LLP
Ms. Alice Baltimore
Jeffrey and Pamela Balton
Mr. Peter Barna
Mrs. Jamie Barton
Battaglia Industries, Inc.
Batza Family Foundation
Mr. Michael J. Batza, Jr.
Mr. Thomas E. Beach
Mrs. Elfriede Beall
Mr. David Beanblossom
Mr. John M. Beard, Jr.

David Becker
Fred Bedard
Mr. and Mrs. Richard Beebe
Mrs. Charity Benton
Elliott H. Berger
Dr. and Mrs. Hans Bergstrom
Mr. and Mrs. Barry Berlin
Beverly Hills Police Officers
Association
Mr. and Mrs. Fred B. Bialek
Ms. Julie Bianchi
Mr. William Biebusch and Mrs. Doreen
Biebusch
Mr. and Mrs. Eugene Blabey
Ms. Kayleigh Blair
Ms. Francine Blau
Mr. and Mrs. Henry R. Bleier
Mr. Robert G. Block
Mr. Robert Blum
Mr. Richard Boland and Mrs. Colleen
Boland
Mr. Omid Bolour
Mr. Bruce H. Botchman
Mr. Lucas Botros
Mr. and Mrs. Richard Bowden
Mr. Stephen Bowen
Mr. Paul F. Boyle
Braman & Associates, Inc.
Mr. and Mrs. Allen Branch
Ms. Julie Brandes
Mr. Gerald Brandi and Mrs. Lynda
Brandi
Mr. Michael Bray and Mrs. Barbara
Bray
Mr. Dennis J. Breen
Mr. Dermot Brennan
Mr. Emil J. Britt, Jr.
Ms. Karen Broadnax
Mr. and Mrs. Albert Brooke
Mr. Andrew F. Brooks
Ms. Jacquelin Brova
Mr. and Mrs. Douglas Brown
Mr. Jono Brown
Mr. Stephen Brown
Mr. Walter W. Brown
David P. and Jerilyn Brownell
Mr. Lawrence R. Bulduc and Mrs.
Shirley A. Bulduc
Mr. Michael Burnley
Mr. Roger Byford
Mr. Joseph Cabral
Craig and Caryn Caffarelli
Mr. Ross Cahn
Ms. Miguelina Calderon
Mr. Roger H. Campbell
Mr. John Carmody
Castaways Foundation
Mr. Al Ceresa
Mr. Marc Cesare
Mr. Akin Ceylan and Mrs. Cyndi Ceylan
Mr. Charles J. Cherre, Jr.
David and Suzanne Chonette
Mr. Caspar Chou
Mr. John F. Ciesielka and Mr. Dale W.
Bottoms
Mr. Stephen Clampett
Ms. Diane Cochran
Mrs. Maggie Coffey
Mr. Steven C. Cohen
Mr. John Cohen

Mr. Robert K. Cohen
 Ms. Christine Cole
 Mr. James H. Cole
 Ms. Jennifer R. Cole
 William S. Comanor, PhD
 Mr. and Mrs. Kurt A. Conti
 Mr. Sean W. Coogan
 Mr. Clay Cook
 Mr. Joe Cover
 Mr. Jeffrey Cox
 Dr. and Mrs. Ross L. Crist
 Mrs. Doris Crouch
 Mr. Alec Dafferner and Mrs. Elizabeth Dafferner
 Mr. Joseph L. D'Amico
 Mr. James A. Davidson
 Mr. Carlton Davis
 Ms. Deanna Deel
 Ms. Rebecca DeLamotte and Mr. Peter H. Bloom
 Dempsey Uniform Linen Supply Inc
 Mr. Dennis Luther and Mrs. Barbara Luther
 Mr. Walter Deriso and Mrs. Anna T. Deriso
 Descartes Labs, Inc
 Mr. B. Dever
 Diapath Spa
 Mr. David A. Dickey
 Mr. Robert A. Dilworth
 Joseph DiNapoli, Sr. Memorial Golf Outing
 Mr. Kai Dittmar
 Mr. Steven L. Dobbstein
 Mr. John G. Dobrez
 Mr. Gilbert Dodson
 Mr. and Mrs. Bruce Donaldson
 Ms. Debbie Doppelt
 Mr. Patrick Doran
 Ms. Diane F. Dotson
 Mr. Don Douglas and Mrs. Carolyne Douglas
 Mr. Joseph Doyle
 Mr. and Mrs. Mark Dreschler
 Mr. and Mrs. William E. Dreyer
 Ms. Tina Driscoll
 Mr. Brian Duchinsky
 Mr. Joseph F. Duerr
 Mr. Michael Duff and Mrs. Meg Duff
 Michael Dunitz Crisis Foundation
 Mr. Sean Durbin
 Mr. Peter J. Durfee
 Mr. James W. Durst
 Mr. William Duttlinger
 Edrington
 Mr. and Mrs. Grant Edwards
 Mr. and Mrs. James W. Eggenberger
 Mr. Pete Eischen
 El Conquistador Mortgage
 Mr. and Mrs. Jeff Elkin
 Mr. Bob Emmelkamp
 Mr. Albert L. Engel and Mrs. Jane M. Engel
 Englewood Cliffs Police
 Enterprise Holdings Foundation
 The Epstein Family Foundation
 Mr. and Mrs. Edward R. Evans
 Evans Insulation Company
 Mr. Peter Evensen and Mrs. Susan Evensen
 Ms. Sandy Fainbarg
 Mr. Robert G. Fair
 Ms. Bayla K. Falber
 Mr. Eric Falkenberg
 Farella Family Fund
 Mr. and Mrs. Michael Farrell
 Mr. Brandon Farris
 Dr. and Mrs. Clyde Farris
 Mr. and Mrs. Mark Feroglia
 Ken and Caryl Field
 Find It Parts
 The Finerman Foundation
 Mr. Jerome Fiore and Mrs. Terri Curtis
 Mr. and Mrs. Howard M. Fischer
 Ms. Sandra Fitzgerald
 Fleetcor
 Fleetcor Tech Operating Co LLC
 Mr. Alan Fodor
 Mr. William Fogle
 Ms. Marian R. Foldberg
 Mr. Peter Foster
 Mr. Jack Foxworth
 Mr. Charles Frankel
 Larson Freitag Charitable Giving
 Dr. and Mrs. Mark H. Fritze
 Mr. and Mrs. William Frumkin
 Mr. William C. Fuller, Jr.
 Mr. Jacob Gantz and Mrs. Leigh Gantz
 Mrs. Nancy H. Gardiner
 Mr. Joshua Gartner
 Mr. and Mrs. J. Donald Garvey
 Mr. Robin Gates and Ms. Jan Fulwiler
 Mr. Anthony Geisler
 Ms. Sheila Germaine
 Mr. and Mrs. Donald A. Gill
 Mr. Pier Giorgetti
 Mr. James Gizzonio
 Mr. and Mrs. David Goetz
 Mr. Raj Gohill
 Ms. Suzanne Gold
 Mr. Myles Goldfein
 Dr. Ronald Goldstein
 Mr. Michael L. Gollobin and Mrs. Laura S. Gollobin
 Ellen M. Golub Charitable Foundation
 Mr. Gary Gordon
 Mr. James Gordon
 John P. Gould and Kathleen A. Carpenter
 Mr. and Mrs. Jonathan P. Goulding
 Mr. Tsahi Gozani
 Mr. Bill Green
 Mr. William L. Gregory
 Mr. Brendan Griffith and Mrs. Lynn Griffith
 Mr. Charles Grimes
 Mr. Thomas Groeninger and Mrs. Elizabeth Groeninger
 Mr. Paul Guagliardo
 Mr. Wayne E. Habeck
 Thomas R. Hagadone and Pamela J. Miller
 Mr. Dana Hagen
 Mr. Robert S. Hagge Jr
 Mr. and Mrs. Raymond A. Haines
 Mr. Rex Hamilton and Mrs. Joan Hamilton
 Mrs. Douglas S. Hansen
 Ms. Julie A. Hansen
 Mr. Nathaniel Hansford and Mrs. Frances Hanford
 Mr. and Mrs. Harold E. Rickards
 Mr. Craig Haskins
 Mr. Andrew Hatter
 Jerry and Marilyn Hayden
 HDR
 Mr. and Mrs. H. Peyton Henderson
 Mr. and Mrs. David P. Henninger
 Hermosa Beach POA
 Mr. and Mrs. Henry G. Herzing
 Mr. Robert F. Hirsch
 Mr. Don Hirth
 Mr. Douglas Hobbs
 The Patsy and Michael Hochman Charitable Foundation
 Mr. William E. Honey
 The Jacobs Institute and the State University of New York Buffalo
 Mr. and Mrs. Larry Horn
 Ms. Aviva Carmy and Mr. Harry Horowitz
 Mr. William Hudnell
 Mr. and Mrs. Jack Hudspeth
 Mr. Kenneth Hukari
 Mr. Robert J. Hunter
 Dr. Ian Jones
 IFI, LLC
 Mr. Rod Jack
 Jacobs Family Foundation
 Mr. Roland Jarmusch
 Mr. Adam Jasperson
 Mr. Jeffery Kane
 Mr. James Jenkins
 Mr. and Mrs. Daryl L. Jespersen
 Mr. and Mrs. John Jester
 Mr. Michael Jones and Mrs. Dorothy P. Jones
 Mr. Thomas G. Kamasky and Mrs. Ann L. Kamasky
 Mr. Barry Kamel and Mrs. Debra Kamel
 Ms. Harisen Kardon
 Mr. Adam Katz
 Mr. Ira Katz
 Mr. Mitchel Katz and Mrs. Meredith Katz
 Mr. Neil Katz
 Keeler Motor Car Company Charitable Foundation
 Mr. Kenneth A. Jones
 Mr. Joseph A. Kiat and Mrs. Penny Kiat
 Mr. and Mrs. John P. Kiley
 Mr. Christopher Kleiman
 Mr. Lloyd Klein
 James W. Klein
 Harold and Shirley Kobliner
 Mr. Matthew Koren
 Mr. Richard S. Kramer
 Mr. Wilson Kriegel
 Dottie and Tom Krull
 KSB Dental
 Mr. Robert Kuepper
 Mr. and Mrs. Frank Kulze
 Mr. James Kuykendall
 La Verne Police Officer's Association
 LA-CO Industries, Inc.
 Lakeland Bank
 Mr. Patrick Lancaster
 Joshua M. Lang, M.D.
 Lucy and Paul Lange, M. D.
 Leading Systems Technologies
 Mrs. Susan L. Lebovitz-Edelman
 Ms. Kay Ledyard
 Ms. Suzanne Leeds
 Mr. Mark Leffers and Mrs. Janine Leffers
 Dr. Daniel Lehman
 Mr. and Mrs. Richard H. Lester
 Mr. George Levie
 Ms. Pin Lin
 Mr. Robert S. Linnell
 Mr. Jack Loeb, Jr.
 Mr. Kevin Lofton
 Mr. Gabriel Loh and Mrs. Susan Loh
 Mr. and Mrs. Gerald A. Long
 Chris and Krista Loose
 Douglas R. Lowe
 Charles Lowrey and Susan Rodriguez
 Mr. Victor Lucadamo
 Mr. and Mrs. Christopher Luetzow
 M & T Charitable Foundation
 Gordon Maahs
 Mr. Michael G. MacKay
 Mr. Mike MacKay
 Mr. Jeff MacLellan
 Mr. Roderick MacLeod
 Make My Donation, Inc.
 Mr. Jacob Mandel
 Ms. Sandra Mantione
 Mr. William D. Marcum
 Mr. Bernardo Mariano, Jr.
 Marlborough Country Club Women's Golf Association
 Stanley and Pamela Maron
 Mr. Douglas G. Martin
 Mr. James Marzen
 Mr. David Mason
 Mr. Daniel May
 Mr. Atwood R. McAndrew, Jr.
 Ms. Juliet McCarthy
 Mr. Frank McClendon
 McCown Family Foundation
 Mr. Mark McCready
 Mr. Brian J. McGuinn
 The McKelvey-Daugherty Family Foundation
 Mr. Mark McKinley
 James and Ann McKinney
 Laureston and Barbara McLellan
 Mr. Patrick and Alicia McMahan
 Mr. and Mrs. Harry McMillan/McMillan and Associates
 Mr. Bryan McQuattie
 Mr. and Mrs. Joseph M. Mego
 Mr. Robert Mehm
 Ms. Barbara J. Meislin
 Mr. Jack Melnicki
 Mr. Mark Mercer
 Mr. and Mrs. Jack Meyers
 Mr. Paul J. Milbury
 Mr. Robert J. Milhiser and Mrs. Carol J. Milhiser
 Ted and Donna Miller
 Mr. Burkhard Mohr
 Mr. Patrick Moore
 Bill Morgan
 Linda and Michael Morgan
 Mr. Robert Moritz
 Mr. George Mueller
 Muller Family Foundation
 Mr. Yevgeniy Muravchik
 Mr. Michael Muzzy

Mrs. Kathleen Myers
 Mr. Pascal F. Tone
 Mr. William H. Neal and Mrs. Gail A. Neal
 Mr. Lou Nekola
 Blake Lee and Carolyn L. Neubauer
 New York Mets Foundation, Inc.
 Karen Preble Nichols
 Mr. Marty Nickison, II
 David P. Nolan Foundation
 Mr. Bret Norton
 Ms. Nancy Novak
 Mr. and Mrs. Thomas L. Oakey
 The Oakland Athletics Community Fund
 Mr. Robert J. O'Block
 Dr. and Mrs. James E. O'Brien
 Mr. and Mrs. Richard Offerdahl
 Mr. David Ogrin
 Old Stump Brewery
 Mr. David Oliver
 Mr. and Mrs. Henry Ondrusek
 One Capital Management, LLC
 Dr. Fernando Otero
 Mr. Thomas Padrick
 Mrs. Sureshrani Paintal
 Mr. Stephen T. Palmason
 Mr. James Paloyan
 Mr. and Mrs. David Panhorst
 Mr. and Mrs. Michael Pansini
 Otto Winzen Memorial Advised Fund of the Catholic Community Foundation
 Mr. Thomas M. Parrett
 Mario and Alma Pastega Family Foundation
 Mr. and Mrs. Toby Paterson
 Steven R. Patierno, Ph.D.
 Thomas J. Patrician
 Mrs. Jennifer Pazzia
 Mrs. Gretchen Pehanick
 Ms. Amy Pelaia
 Pelican Pointe Mens Golf Association
 Performance Imaging
 Mr. and Mrs. Mark Peterson
 Mr. David D. Peterson
 Cynthia M Petitjean PL Trust Account
 Daniel P. Petrylak, M.D.
 Mr. Alec Pettersen
 Mr. Bernard L. Pfefer
 Ms. Sharon Pipes
 Mr. Chris Pollack
 Mr. Harold Pollin
 Mr. David Polnaszek
 Mr. John Poth
 Powell Family Foundation
 Gail S. Prins, Ph.D.
 The Rabinowitz Foundation
 Mr. William R. Racine and Mrs. Nancy G. Racine
 Mr. and Mrs. John Raffetto
 Muhit and Anna Rahman
 Mrs. Lori Ramani
 Mr. Michael Rao
 The Rapaport Family
 Mr. and Mrs. Warren Rasmussen
 Mr. and Mrs. Perry E. Raso
 Mr. Cotton Rawls Jr
 Mr. Mark Recoulley
 Mr. and Mrs. Randy Reedy
 Patty and Doug Reid Family Foundation Inc.
 Mr. Edward Reis
 Dr. Thomas Resnick and Mrs. Barbara Resnick
 Mr. Tyler Ridgeway
 Major Charles N. Riley
 Mr. Jonathan M. Rin
 Mr. Timothy M. Ring
 Mr. Ben Rizzi
 Mr. Michael J. Roach
 Mr. and Mrs. Michael Rochester
 Mr. James Roland
 Mr. Robert Rosenbaum
 Mr. and Mrs. Robert Rosenberg
 Mr. William Rosenfeld and Mrs. Sandra Rosenfeld
 Rosenthal Family Charitable Fund
 Mr. and Mrs. Edward Ross
 Mr. and Mrs. Chris J. Rufer
 Ms. Erica Rusnock
 Russelectric Inc.
 Mr. Joshua Russo
 Mr. and Mrs. Gerard M. Ruvo
 Mr. Robert Sachs
 Rodman V. Safeway Escrow Account
 Dr. and Mrs. Robert N. Saito
 Mr. and Mrs. Basil Salaymeh
 Mr. Andy Salk
 Mrs. Sandra M. Salka
 Mrs. Sandra Jonas
 Theodore Sands
 Mr. Shamba Sandy
 Mr. Tod Sanger
 Mr. Jeffrey M. Savino
 Dr. Paul Schimmel
 Mr. Mark Schlau
 Mr. and Mrs. John E. Schlitt
 Mr. Frederick W. Schmid, Jr.
 Mr. Phil Schneider
 Mr. David Schreiner
 Mr. Ken Schroeder and Mrs. Barbara A. Schroeder
 Mr. Martin Schwartz
 Dr. and Mrs. Fred W. Scott
 Mr. Gary L. Seacrest
 Mr. Robert Seibold
 Sellers Publishing, Inc.
 Miss Nicole Serene
 The Wilson Sexton Foundation
 Mr. Harvey Shanbaum
 Mr. and Mrs. Michael F. Shanley
 Mr. John Shannon
 Mr. Michael Share
 George and Helena Shen Foundation
 Mr. Gregory Shenkman
 Mr. Joseph Shiman, III
 Mr. E. Michael Shine
 Dr. and Ms. Joel Shoolin
 Mrs. Anna Marie Siegmann
 Mr. Bob Silverman and Mrs. Lois Silverman
 Mr. James Simmons
 Mr. Marc V. Simons
 Mr. Michael Sirek
 Mr. Kenneth Sirlin
 Mr. Albert Smith and Mrs. Maureen Smith
 Dr. David Smith
 Mr. David Smith
 Mr. Henry Smith
 Mr. Kenneth Smith
 Mr. and Mrs. Chandler Snell
 Dr. William E. Snowden
 Ms. Karen R. Sobel
 Mr. and Mrs. Michael A. Sommer
 Mr. Jonathan R. Soohoo
 Mr. James Spalding
 Mr. Robert Spatt
 Mr. Daniel Sperling
 Mr. Robert I. Spiegel
 St. John's Orthodox Church of India
 Mr. Joseph E. Kane and Ms. Carol M. Stamps
 Mr. Paul Stapleton
 Mr. George Stark
 Mr. Murray Stark
 Starkey Sports Consulting, LLC
 Mr. and Mrs. John Strizver
 Mr. Kyle Stromberg
 Mrs. Susan B. Strong
 Styles of Steppin'
 Mr. and Mrs. Ronald Styn
 Sun Home Services, Inc.
 Mr. Seth Swerdlow
 Mr. and Mrs. Tab E. Johnson
 Mr. Richard A. Tanovich
 Mr. Vincent Taormina
 Mr. Adrian Taylor
 Mr. John J. Tegan, Jr.
 Steve Tino
 Ms. Marilyn Titus
 Stephen G. Tolchin
 Mr. Bradley Tolkin
 Mr. William Toomajian
 Mrs. Teresa Torpey
 Ms. Miraida L. Torres
 Mr. Peter L. Townsend
 Township of Union Police Department
 Ms. Vanessa Trancoso
 Dr. Gilbert Traub
 Mr. Mark Treska
 Mr. Robert Tsieng
 Mr. Neil Tucker and Mrs. Mindy Tucker
 Mr. Scott Turban
 Mr. and Mrs. Knight Tuttle
 TVG Executive Search
 Mr. James Tyler
 Mr. Robert Ufland
 UGI Energy Services, LLC
 Ms. Lynn Umbreit and Mr. Bruce Haibach
 United Way of Coastal Fairfield County, Inc.
 University College London
 Mr. Robert Urban
 Us TOO Prostate Cancer Support Group - Suffolk County
 Mr. James Vanlandingham
 Mr. Mike Vanneman
 Vantrust Real Estate, LLC
 Mr. Alberto Vega
 Mr. and Mrs. John Veiga
 Mr. Marcel Verbaas
 Meryle and Daniel Verner
 Mr. Jon Visser and Mrs. Robin Visser
 Mrs. Andrea M. Wade
 Mr. and Mrs. Roger P. Wagner
 Mr. and Mrs. Douglas O. Waikart
 Mr. Timothy R. Wallace
 Mr. and Mrs. Milton J. Walters
 Shaomeng Wang, Ph.D.
 Mr. David L. Warfel
 Mr. Simon Warren
 Mr. and Mrs. Charles Wax
 The Robert F. Weinberg Family Fund
 Michael and Jill Weinstein
 Mr. Steven B. Weinstein
 Jane Weintraub Trust
 Dr. Richard E. Weisblatt
 Mr. Thomas Weisenfels
 Dr. and Mrs. Howard Weiss
 Ms. Renata Weiss
 Mr. and Mrs. Seymour Weiss
 Mr. Fredric Weiss
 Welk Resorts - San Diego
 Mr. and Mrs. Charles Westley
 Mr. and Mrs. Nigel Weston
 Mr. Justin Whalen
 Mr. Jason White
 Martin Wice
 Mr. Steve Williams
 Mr. David Williamson
 Mr. John Wilson
 Mr. Wayne C. Wilson
 Wine Pull 2019
 Matthew and Elizabeth Winkler
 Andrew Wise
 Ms. Sheri Wise
 Mr. Roger Wood
 Ms. Amy Wood
 Mr. and Mrs. Bruce Wooley
 Mr. J. L. Woolf
 Mr. and Mrs. Richard J. Wright
 Mr. Richard Wright
 Mr. and Mrs. Harry Yeaggy
 Mr. Gregory Zedlar
 Mr. Gary Zellerbach
 Mr. and Mrs. Raymond Zimmerman
 Mr. Anthony Zumbano and Mrs. Kathy Zumbano
 Mr. and Mrs. Stephen Zynda

PCF Community Fundraisers

Participants who raised \$1,000 or more

Andy Astrachan
 Aux Sable Liquid Products LP
 Julie Rose Dodson Baisinger
 Baker Botts, LLP
 Brandon's Bourbon
 Catherina Brown and Styles of Steppin' Seattle
 Ken J. Buck and Mrs. Cathleen A. Buck
 Marie Eilen and the Ghayal Family
 Don Eilenberger
 Fleetcor
 Dave Fleming and Craig Bell
 Gohill Orthodontics
 Dan Haase
 Kelly Hayes
 Hernando Firefighters Benevolent Relief Fund
 Tyler Holden
 Hooked on Driving: Derric's Day
 HOPE Motorcycle Rally
 Raymond Hwang and the Hwang Family
 Joseph, Penny and Colin Kiat

Ed Kloskowski
 Dr. Edward and Ina Loftspring
 Courtney Maguire
 Hayes McCaffrey and the Lee Family
 Old Stump Brewery
 Profound Medical
 Chris Remensperger
 Ivars Rinkis
 Erica Rusnock
 Liliana Sarmiento
 Anna Marie Siegmann
 Ramiro Siliezar
 Lisa Silver and The Silver Lining
 Stephen Tendrich and The Pink Nail Society
 Miraida Torres
 Valencia Turney and the Turney Family
 Dave, Ben, Luke, and Cale Updegrave
 Rachel Vaizer
 Jerry Walters
 Becky Wegner

Blue Ribbon Golf Tournaments

Golf tournaments that raised \$1,000 or more

10th Annual Pros4Care - Texas
 12th Annual HLT Texas Shootout
 13th Annual FLHW Golf Tournament
 5th Annual 19th Hole Classic
 8th Annual C.A.R.E. Golf Outing
 8th Annual Jay Moody Memorial
 8th Annual Sadie Hawkins GT
 Annual Prostate Cancer Research Invitational
 Battle at Addison Reserve
 Battle at Bella Vista
 Battle at Brookhills
 Battle at Burlington & Rally for the Cure
 Battle at Canoe Brook
 Battle at Palm Beach
 Battle at Pelican Pointe
 Battle at Rarity Bay
 Battle at the Meadow Club
 DSB Invitational
 El Conquistador Prostate Cancer Tournament
 Friends of Dermot Brennan
 Joseph DiNapoli, Sr. Memorial GT
 Lehigh Valley MGA
 Luetzow Charity Golf Outing
 Opening Day Golf Tournament
 Palm Aire Prostate Tournament
 Save the Balls FORE PC
 Sheffield Pharma for PC Research
 Sweetwater Mens Cancer Tournament
 University Park Member-Guest for PCF
 Wild Dunes MGA Member/Guest
 Willowbrook RCM Memorial
 Wycliffe CC MGA

Blue Ribbon Society

Our community of monthly donors

Anonymous
 Mr. Steve M. Abbott and Mrs. Diana M. Abbott
 Mr. Steven Aberblatt
 Mr. and Mrs. Hal Absher
 Mr. Robert M. Agans
 Mr. Larry Aiken
 Mr. Mohamed Alhammadi
 Mr. Donald Allen
 Mr. Dean Ambrose and Mrs. Dianne Ambrose
 Mr. Paul N. Anderson
 Mr. Paul Anderson
 Mr. M. Douglas Archer and Mrs. Pat Archer
 Ms. Christine Auerbach
 Mr. Michael Bankert
 Mr. Stephen Y. Barrow
 Mr. Tom Barton
 Mr. Mark Bass
 Mr. Donald Beier
 Mr. Percy B. Bell
 Mr. Barry Berglund
 Mr. Dennis E. Bernard
 Mr. John P. Bernier and Mrs. Donna Bernier
 Mr. Richard H. Bickerstaff
 Mr. Michael Bigini
 Mr. Michael Bivens
 Mr. Robert Blum
 Mr. Steve Borowski
 Mr. Raymond Boyce
 Mr. Laurence Brady
 Mr. Jerald Brannon
 Mr. and Mrs. Gerald Brenke
 Mr. Robert T. Brew, Jr.
 Ms. Dakota Briggs
 Mr. Ramon Bristol Castrillon
 Mr. John Brophy
 Ms. Amanda Brown
 Mr. Scott C. Brown
 Mr. Stuart P. Brown and Mrs. Jeanine Brown
 Mr. George Brucks
 Mr. Henry L. Burks and Mrs. Diana Burks
 Ms. Patricia Burton
 Mr. Joe Butler
 Mr. Roger Byford
 Mr. Danny A. Byler and Mrs. Rose Byler
 Mr. Sean Caillias
 Mrs. Amy Caimano
 Mr. Ernest Campos
 Mr. Frank V. Cardone and Mrs. Adrienne Cardone
 Mr. Steve Carney
 Mr. David P. Carosella
 Mr. William Carr and Mrs. Jean Carr
 Mr. David Cassino
 Mr. Howard Chai
 Mr. Gary Chamblee
 Mr. Lou Chapman
 Mr. Steven Chapman
 Mr. Scott Chaudoir and Mrs. Lisa Chaudoir
 Mr. Arthur P. Chimes
 Mr. Jeff Chinn

Mr. Graham Church
 Mr. Matthew Cifichiello
 Mr. James H. Cole
 Ms. Tama Coleman
 Mr. Cory Compton and Mrs. Jacqueline Compton
 Mr. Michael Conway
 Mr. Clay Cook
 Mr. and Mrs. Steven Cooper
 Mr. and Mrs. Stephen Cornes
 Mr. Ted Costa
 Mr. Michael Costin
 Mr. Craig J. Couture
 Mr. Bruce Cox
 Mr. Charles E. Cree
 Mr. Thomas Czajkowski
 Mr. Randy Datsko
 Mr. Gene Dawson
 Mr. Robert Dean
 Mr. Thomas Del Prato
 Ms. Dorothy Delarm
 Mrs. Julie Dodson Baisinger
 Mr. Todd J. Dokken
 Mr. Don Douglas and Mrs. Carolyne Douglas
 Rich Downen
 Dr. Korsi Dumenyo
 Mr. and Mrs. Gary Dummitt
 Ms. Sandra Duncan
 Dr. Thomas D. Easley
 Mr. Willard Easton and Mrs. Joyce Easton
 Eden Formulations
 Mr. Ehigie Enakhimion
 Mr. Kenneth L. English
 Dr. John Farnsworth
 Mr. Warren Fauver
 Mrs. and Mr. Esther Federman
 Mr. and Mrs. Daniel J. Feiner
 Mr. Ralph Ferrara
 Mr. Carlos Ferrer
 Mr. Tom Fever
 Mr. Greg Fishwick
 Dr. Rich Fonda
 Mr. and Mrs. Richard Forchetti
 Mr. Richard Fournier
 Mr. Thomas Frankforter
 Mr. Anni Freeman
 Mr. Robert Frewing
 Mr. Max Fuentes
 Mr. Thomas Fuller
 Mr. and Mrs. Robert Gain
 Mr. Herbert M. Gant
 Mr. David A. Gerber
 Miss Rose Gilman
 Mr. Ryan Gilmartin
 Mr. and Mrs. James Gioffe
 Mr. Joel Goldberg
 Mrs. Joyce Gonzales
 Mr. Charles W. Gossett
 Mr. Robert Greenbaum and Mrs. Heidi Greenbaum
 Mr. Michael D. Grills
 Ms. Carmen Hall
 Ms. Julie A. Hansen
 Mrs. Hope Hare
 Mr. David Harvey
 Mr. Kent L. Hastings and Mrs. Libby Hastings

Mr. William R. Hasty and Mrs. Sara Hasty
 Dr. George Hatch
 Ms. Linda Hayes
 Mr. and Mrs. John Hazen
 Mr. Barry L. Heath
 Ms. Corrie Henderson
 Mr. Richard Henderson
 Mr. David Herndon
 Dr. Paul Hesse
 Mr. Joseph Hewell
 Mr. Jeff Hewitt
 Mr. Bradford L. Hillegass
 Mr. Nevin Hoke
 Mrs. Jody Horwitz
 Mr. Robert Horwitz
 Mr. Gary House
 Mr. Justin Hughes and Mrs. Adrienne Hughes
 Mr. Michael R. Hund and Mrs. Linda Hund
 Mrs. Christine M. Hunter
 Dr. George Hurwitz and Mrs. Karen Hurwitz
 Lt. Luke W. Jean
 Mr. James Jenkins
 Mr. Alfred John
 Mr. Randall John
 Mr. Dale L. Johnson
 Mr. David Johnson and Mrs. Lynda Johnson
 Mr. and Mrs. Mark W. Johnson
 Mr. Robert A. Johnson and Mrs. Paula Johnson
 Mr. Roger A. Jones
 Mr. Tom Joplin and Mrs. Shannon Joplin
 Dr. Robert R. Jorgensen and Mrs. Dorothy Jorgensen
 Mrs. Michael I. Joseph
 Mr. Scott Jurgens
 Mr. and Mrs. Gary Kasper
 David Kechley
 Mr. Damian J. Kelly
 Dr. Betty Kennebrew
 Mr. Joseph Keyes
 Dr. Haydn Kissick
 Mr. William D. Kleeman
 Mr. Curt Koopman
 Mr. Winston Kou
 Mrs. Mary Kowalski
 Dr. Robert A. Kraft
 Mr. and Mrs. Mark Kraus
 Mrs. Maureen M. Kuntze
 Ms. Sherry Langdon-Crookendale
 Mr. Albert Latini and Mrs. Madelaine Latini
 Mr. George Lee
 Mr. Teng-Kiat Lee
 Mrs. Janet Lehoullier
 Mr. Steven Leonido-John
 Mr. John A. Lever
 Mr. Todd Lewandowski and Mrs. Kirsten Lewandowski
 Dr. Tom Lewis
 Mr. Andrew Lippman
 Dr. William Lockhart
 Mr. Jack Loeb, Jr.
 Dr. Blair Lonsberry
 Mr. Robert Lorion
 Mr. Garry Louers, Sr.

Mr. John Lowenthal
 Mr. Michael G. MacKay
 Mr. John Makemson
 Mrs. Tania J. Malven
 Mr. Jacob Mandel
 Ms. Andrea Marsh
 Mr. David Mason
 Mr. Dean K. Mathis
 Mr. Gary Matthews
 Mr. Stephen Matthie
 Mr. Joseph Mazzeo
 Mr. Herman McBurrows
 Capt. William T. McCluskey
 Drew A. McCready
 Mr. Steven McDonald
 Mr. Brent Mcelwain
 Mr. Norman J. Meier
 Mrs. Jacqueline Melendez
 Mr. Joe Merhib
 Mr. Luke Metaxas
 Mr. John Mihalchik
 Mr. Dean Minard
 Ms. Denise Moad Hollingsworth
 Mr. Freeman M. Montaque, Jr.
 Mr. Tom Moots
 Mr. and Mrs. Dennis G. Morgan
 Mr. Scott Morgan and Mrs. Rhonda Morgan
 Todd M. Morgan, M.D.
 Mr. John E. Moseley and Mrs. R Victoria Moseley
 Mr. and Mrs. Richard L. Murphy, III
 Mr. Vito A. Mussomeli
 Mr. Gary Nawrocki
 Mrs. Maura Needham
 Ms. Kathy Nickerson
 Ms. Sarah Noon
 Mr. Francis Jerry Norder
 Mr. Steven Nordstrom
 Mr. Raymond V. O'Connor, Jr.
 Mr. Michael Olds
 Capt. Phillip Olsen
 Mr. Dennis Ortlund
 Mrs. Mary H. Ott
 Ms. Samantha Ott
 Gerald Pace
 Mr. Thomas Padrick
 Mr. James Paloyan
 Mrs. Kathleen Paren
 Dr. Cecil Payton
 Mr. Mark Payton
 Mr. Robert Peach
 Mr. Mark Persson and Mrs. Janice Persson
 Mr. James Peterson
 Mr. James T. Pizzo and Mrs. Laura Pizzo
 Mr. Joshua Pledger
 Mr. John Plunkett
 Mr. Michael Popadiuk
 Rev. William W. Prior and Mrs. Mary Prior
 Mr. Sachin Purekar
 Mr. Bradley Quale
 Mr. Frank Quale
 Mr. Ben J. Rainbolt
 Mr. Marcio L. Rangel
 Dr. and Mrs. Jerry Rauch
 Dr. and Mrs. Ralph J. Rauch
 Mr. Mark Recoulley

Ms. Leddy Renwick
 Mr. Gerard Reynolds
 Mr. Riley Rice
 Ms. Kathryn Rittweger
 Mr. Wilberto Rivera
 Mr. Dan J. Roessner
 Ms. and Dr. Jeanne Rose
 Mr. Kenneth I. Rose, III
 Mr. Scott Rosenberg
 Stan and Patti Rosenfeld
 Ms. Irene Rosenthal
 Mr. and Mrs. Jeffrey D. Roth
 Mr. Rudolf Rottenfusser and Mrs. Hanna Rottenfusser
 Mr. Blair Samuelson
 Mr. Joseph Sander
 Mr. Tod Sanger
 Mr. Jim Scarantino
 Dr. Richard Schatz
 Dr. Michael Scheerer
 Mr. and Mrs. Kenneth Schofield
 Ms. Heather Sellars-Wilson
 Mr. William Sellin
 Mr. Paul Senecal and Mrs. Pamela Senecal
 Mr. Hoyle Setzer
 Dr. David M. Shames
 Mr. Michael Sheline
 Mr. Robert H. Sherman and Mrs. Corrine Sherman
 Mr. Joseph Shiman, III
 Mr. Anthony Simms
 Mr. Randolph Sinquefield
 Dr. Kirk H. Smith
 Mr. Mark C. Smith
 Mr. Mike Smith
 Mr. Paul Smith
 Ms. Rebecca Snyder and Mr. Mark Fawcett
 Mr. Terry Staebell
 Mr. Lee Stahl
 Mr. Leland L. Stanford
 Lesley and Robert Stern
 Gary Stoneburner
 Jodie Street
 Mr. Donald Stroh and Mrs. Tracy Stroh
 Mr. Emmett Sullivan
 Mr. Seth Swerdlow
 Mr. and Mrs. Richard W. Szilasi
 Ms. Ethio Tare
 Mr. David Taylor
 Mr. Nicholas Taylor
 Tim Tengvall
 Mr. Paul A. Thiede
 Mr. Charles Thomas
 Mr. Kenneth Thomas
 Ms. Andrea Thompson
 Mr. Belal M. Tiba
 Mrs. Karla Toomey
 Mr. George C. Torres and Mrs. Colette Torres
 Mr. Bang Tran
 Mr. James Troll
 Mrs. Jennifer Trujillo
 Mr. Duane E. Trump and Mr. Edan Trump
 Mr. Joel Turbin
 Dr. Nicholas Uliano
 Mr. Thomas R. Utesch and Mrs. Jetta Utesch

Mr. Ryan Uyehara
 Mr. Heinrich Vaseur
 Mr. John Virginio
 Mr. Fred D. Walker, Jr.
 Mr. Demonso A. Waters, Sr.
 Mr. Kevin Webb
 Mr. Jeff Weemhoff
 Mr. Donald Welch
 Mr. Dennis J. White
 Mr. Drew Whittington
 Mr. Dave Wilder and Mrs. Mary Wilder
 Mr. Lawrence Williams
 Mr. and Mrs. Howard J. Willis
 Mr. Shawn Wilson
 Mr. Wayne K. Wilson and Mrs. Renate Wilson
 Mr. Ken Wiseman
 Mr. Leslie Wood
 Mr. Robert Yebuah
 Mr. Colin Young
 Mr. Felix Zemel
 Mr. Robert F. Zuppert and Mrs. Emily Zuppert

Anthony L. Pantera
 Mark A. Perrelli
 Harlan Pruger
 Lawrence M. Rhodes
 Alton J. Sadler
 James H. Scheper
 William G. Schmidt
 Douglas H. Simpson
 James T. Sloan
 Reed B. Somberg
 Frederick J. Stabbert
 Richard L. Starkey
 Lawrence J. Stupski
 Tim Taylor
 Robert Temple
 Lawrence Thalmann
 Gary W. Titus
 Jay L. Wallberg
 Jerry Weintraub
 Janet O. White
 Robert H. Young
 David W. Zauel

Memorial Tribute Funds

Funds that contributed \$1,000 or more

In Memory of:

Nathan Baden
 Roddy Brennan
 Daniel J. Brown
 William G. Bryant
 Kent C. Buehner
 Ralph Bushnell
 Steven P. Caley
 Gary Colbert
 Stephen S. Cole
 Jerry J. Commisso
 Larry G. Cornell
 Chuck Crist
 Moti S. Daswani
 Thomas F. Delaney
 Jimmy Ray Dieringer
 Joseph P. DiNapoli
 Bud Dunham
 Harry Falber
 Stuart Flome
 Miles D. Freitag
 Edward Gal
 Harold Gantz
 John G. Gilmour
 Sally Goldman
 Robert E. Goulding
 Leo F. Griffin
 Daryl Gross
 John Haas
 Frank J. Heidler
 Thomas Hendricks
 Raymond W. Hine
 Andrew Hruszkewycz
 Thomas E. Jones
 George P. Kelley
 Daniel R. Kramer
 James L. Leachman
 Vincent Lombardi
 David B. Longson
 Chester C. Lucido
 Robert C. Mabry
 Britt M. Moffett
 Ezra Novak

Honorary Tribute Funds

Funds that contributed \$1,000 or more

In Honor of:

Elliott Abramowitz
 Ronald Aroesty
 Dennis Barnett
 Bijan Broukhim
 Mo Budak
 Michael Cotton
 Neil P. DeFeo
 Chas Edelstein
 Ronald Evans
 R. Christian B. Evensen
 Tom Griffith
 Chuck Hebard
 Stuart Holden
 Jou G. Hwang
 John Kain
 Stuart Kaplan
 Drew Katz
 Phillip Lee
 Jeffrey Letzler
 Edward Loftspring
 Eric Luse
 Jerome Meislin
 Michael Milken
 Nelsen Money
 Gene Monroe
 Patrick Morgan
 Paul R. Murphy
 Robert Paterson
 Donald D. Pelia
 Howard F. Perrone
 Kenneth J. Pienta
 Jonathan W. Simons
 Donald Sirek
 Steve Sutton
 Joe Wingt

Represents annual donations (gifts, not pledges) between January 1, 2019 and December 31, 2019.

2019 Research Awards

Expanding PCF's Global Research Enterprise



All attendees, representing 18 countries, at the 26th Annual PCF Scientific Retreat on Friday, October 25, 2019

PCF YOUNG INVESTIGATOR AWARDS

The achievements of PCF Young Investigators represent some of the most game-changing work in all of cancer research. They keep the field of prostate cancer research vibrant with new ideas. In 2019, PCF funded 30 new Young Investigators. By mid-year 2019, PCF had funded a total of 287 Young Investigators since the program began in 2007, representing \$58.2 million in research funding.

2019 National Cancer Institute– PCF Young Investigator Award

Remi Adelaiye-Ogala, PhD
National Cancer Institute (NCI), Bethesda, MD

2019 Meitar-IPMN–PCF Young Investigator Award

Elham Afghani, MD, MPH
Johns Hopkins University, Baltimore, MD

2019 National Cancer Institute–PCF **VAlor Young Investigator Award**

Mike Beshiri, PhD
National Cancer Institute (NCI), Bethesda, MD

2019 Terry Laughlin and Regina Aldisert–PCF **VAlor Young Investigator Award**

Mehmet Bilen, MD
Emory University, Atlanta, GA

2019 Greg Brown–PCF Young Investigator Award

James Byrne, MD, PhD
Harvard: Brigham and Women's Hospital, Boston, MA

2019 Merck/AstraZeneca–PCF Young Investigator Award

Arianna Calcinotto, PhD
Institute of Oncology Research, Bellinzona, Switzerland

2019 Nan and Elliot Abramowitz–PCF Young Investigator Award

Goutam Chakraborty, PhD
Memorial Sloan Kettering Cancer Center, New York, NY

2019 PCF Young Investigator Award

Year 1 – Thomas Milana, Jr.

Year 2 – Keith Frankel

Year 3 – Ted Virtue

Catherine Coombs, MD

University of North Carolina, Chapel Hill, NC

**2019 Michael and Patricia Berns–
PCF Young Investigator Award****Matthew Dallos, MD**

Columbia University Medical Center, New York, NY

2019 PCF VALor Young Investigator Award

Year 1 – Roxann Taylor

Year 2 – Michael DeAddio

Year 3 – Thomas H. Lee

Navonil De Sarkar, PhD

Fred Hutchinson Cancer Research Center, Seattle, WA

2019 PCF Young Investigator Award

Year 1 – Joe Barrata

Year 2 – Tim Connors

Year 3 – Joe Jacobs

Arianna Giacobbe, PhD

Columbia University Medical Center, New York, NY

**2019 Young's Market Company–
PCF Young Investigator Award****Gavin Ha, PhD**

Fred Hutchinson Cancer Research Center, Seattle, WA

**2019 Art Kern and John Paulson–
PCF Young Investigator Award****Junjie Tony Hua, PhD**

University of California, San Francisco, San Francisco, CA

**2019 John Black Charitable Foundation–
PCF Young Investigator Award****Anuradha Jayaram, MBBS**

University College London Cancer Institute, London, England

2019 Igor Tulchinsky–PCF Young Investigator Award**Jangun Jo, PhD**

University of Michigan, Ann Arbor, MI

**2019 ASTRO–PCF Career Development Award to End
Prostate Cancer****Amar Kishan, MD**

University of California, Los Angeles, Los Angeles, CA

2019 PCF VALor Young Investigator Award

Year 1 – The Citrone 33 Foundation

Year 2 – George Walker

Year 3 – Mark Weinberger

Steven Kregel, PhD

University of Michigan, Ann Arbor, MI

**2019 John Black Charitable Foundation–
PCF Young Investigator Award****Damien Leach, PhD**

Imperial College London, London, England

2019 Larry Leeds–PCF Young Investigator Award**Deli Liu, PhD**

Weill Cornell Medicine, New York, NY

2019 PCF Young Investigator Award

Year 1 – Fred Luddy

Year 2 – Andrew Weinberg

Year 3 – Jeremy Coller

Francesca Lorenzin, PhD

Università degli Studi di Trento, Trento, Italy

**2019 Republic National Distributing Company (RNDC)–
PCF Young Investigator Award****Patrick Pilié, MD**

The University of Texas MD Anderson Cancer Center, Houston, TX

2019 Clay Hamlin–PCF Young Investigator Award**Raffaella Pippa, PhD**

Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA

2019 Tony D. Minella–PCF Young Investigator Award**Pasquale Rescigno, MD**

Institute of Cancer Research, Royal Marsden Hospital, London, England

2019 Igor Tulchinsky–PCF VALor Young Investigator Award**Jeremy Shelton, MD**

University of California, Los Angeles, Los Angeles, CA

2019 Chris and Felicia Evensen–PCF Young Investigator Award**Eugene Shenderov, MD, PhD**

Johns Hopkins University, Baltimore, MD

2019 Meitar–IPMN–PCF Young Investigator Award**Lilac Tene, M.Med.Sc.**

Maccabi Big Data Center, Tel Aviv, Israel

**2019 Eric Klein and Canadian Coalition to Cure Prostate
Cancer (CCPC)–PCF Young Investigator Award****Daksh Thaper, PhD**

University of British Columbia, Vancouver, BC

2019 Meitar–IPMN–PCF Young Investigator Award**Bo Tu, PhD**

Fred Hutchinson Cancer Research Center, Seattle, WA

2019 David Fleischer–PCF Young Investigator Award**Xiao Wei, MD**

Harvard: Dana-Farber Cancer Institute, Boston, MA

2019 Progenics Pharmaceuticals–PCF Young Investigator Award**Yukiko Yamaguchi, PhD**

City of Hope, Los Angeles, CA

PCF CHALLENGE AWARDS

In 2019, 17 Challenge Award teams were funded by the Foundation. Through peer reviews, PCF selected these projects out of 92 proposals from highly qualified research teams at 58 prestigious cancer centers located in nine countries. The Class of 2019 Challenge Awards represents an investment of nearly \$16 million in advanced prostate cancer research.

2019 Movember–PCF Challenge Awards

Co-Principal Investigators:

John K. Lee, MD, PhD

Fred Hutchinson Cancer Research Center, Seattle, WA

Peter Nelson, MD

University of Washington, Seattle, WA

Goal: *To develop and test the clinical efficacy of a novel LICAM-targeting CAR T cell immunotherapy for the treatment of small cell neuroendocrine prostate cancer*

Co-Principal Investigators:

Eliezer Van Allen, MD

Harvard: Dana-Farber Cancer Institute, Boston, MA

Deborah Schrag, MD, MPH

Harvard: Dana-Farber Cancer Institute, Boston, MA

Wassim Abida, MD, PhD

Memorial Sloan Kettering Cancer Center, New York, NY

Nikolaus Schultz, PhD

Memorial Sloan Kettering Cancer Center, New York, NY

Goal: *To develop digital prostate cancer data platforms that can be used to predict patient outcomes and match patients with optimal precision medicine clinical trials*

2019 Movember / Distinguished Gentleman's Ride–PCF Challenge Award

Principal Investigator:

Charles Drake, MD, PhD

Columbia University, New York, NY

Goal: *To determine the clinical and biological effects of combining a novel IL-8-targeting immunotherapy, the checkpoint immunotherapy nivolumab, and hormone therapy, in patients with hormone-sensitive recurrent prostate cancer*

This Challenge Award has also been co-funded by the Stewart J. Rahr Foundation

2019 PCF Challenge Awards

Co-Principal Investigators:

Sarki Abdulkadir, MD, PhD

Northwestern University, Chicago, IL

Gary Schiltz, PhD

Northwestern University, Chicago, IL

Goal: *To develop a new class of therapies against the critical cancer-promoting gene MYC, for the treatment of prostate cancer and many other types of cancer*

Award Donor: Sun Pharma Global FZE (SPGFZE)

Co-Principal Investigators:

Andrea Alimonti, MD

Institute of Oncology Research, Bellinzona, Italy

Johann de Bono, MD, PhD

Institute of Cancer Research, Royal Marsden Hospital, London, England

Goal: *To determine the mechanisms by which myeloid-derived suppressor cells drive prostate cancer growth and test the clinical efficacy of an inhibitor of IL-23, a major tumor-driving protein produced by these cells*

Award Donors: Stewart J. Rahr Foundation and various other donors

Co-Principal Investigators:

Gerhardt Attard, MD, PhD

University College London Cancer Institute, London, England

Noel Clarke, MBBS

The Christie NHS Foundation Trust, Manchester, England

Mahesh Parmar, MSc

University College London Cancer Institute, London, England

Goal: *To develop clinical-grade biomarkers to identify patients with metastatic hormone sensitive prostate cancer who should receive androgen deprivation therapy (ADT) alone vs. ADT + an androgen receptor-targeted therapy*

Award Donor: John Black Charitable Foundation

Co-Principal Investigators:

Johannes Czernin, MD

University of California, Los Angeles, Los Angeles, CA

Matthew Rettig, MD

University of California, Los Angeles, Los Angeles, CA

Caius Radu, MD

University of California, Los Angeles, Los Angeles, CA

Goal: *To optimize the clinical use of PSMA-targeted radionuclide therapy and identify new combination treatment approaches that overcome therapeutic resistance*

Award Donor: Janssen Pharmaceuticals

Co-Principal Investigators:

Joshua Lang, MD

University of Wisconsin, Madison, WI

Steve Cho, MD

University of Wisconsin, Madison, WI

David Jarrard, MD

University of Wisconsin, Madison, WI

Kenneth Pienta, MD

Johns Hopkins University, Baltimore, MD

David Quigley, PhD

University of California, San Francisco, San Francisco, CA

Goal: *To identify mechanisms and biomarkers of responsiveness of high-risk primary prostate cancers to treatment with docetaxel + hormonal therapy*

Award Donors: Herbert V. Kohler and various other donors

Principal Investigator:

Donald McDonnell, PhD

Duke University, Durham, NC

Goal: *To develop novel treatments and strategies to target the prostate cancer driver HOXB13*

Award Donors: Patrice and Precious Motsepe and the Stewart J. Rahr Foundation

*Co-Principal Investigators:***Hao Nguyen, MD, PhD**

University of California, San Francisco, San Francisco, CA

Peter Carroll, MD, MPH

University of California, San Francisco, San Francisco, CA

Davide Ruggero, PhD

University of California, San Francisco, San Francisco, CA

Goal: *To determine the biology by which the gene expression regulators eIF4E and eIF4A drive prostate cancer growth and whether they have potential as therapeutic targets***Award Donors:** Michael and Iris Smith, Todd Boehly, John Paulson, and various other donors*Co-Principal Investigators:***Li Xin, PhD**

University of Washington, Seattle, WA

Peter Nelson, MD

University of Washington, Seattle, WA

Calvin Kuo, MD, PhD

Stanford University, Stanford, CA

Goal: *To identify proteins in the WNT pathway that play role in prostate cancer biology and have potential as therapeutic targets***Award Donors:** Patrice and Precious Motsepe, The Citrone 33 Foundation, Fuego Box, Louis Graziadio, and various other donors**2019 PCF VALor Precision Oncology Center of Excellence Awards****The Edward P. Evans Precision Oncology Center of Excellence Award***Principal Investigator:***João Ascensão, MD, PhD**

Washington DC VA Medical Center, Washington, DC

2019 PCF VALor Challenge Awards*Co-Principal Investigators:***Veda Giri, MD**

Thomas Jefferson University, Philadelphia, PA

Stacy Loeb, MD

New York University, New York, NY

Goal: *To develop tools to educate physicians, patients and the public on prostate cancer genetics and identify patients who should undergo genetic counseling and testing***Award Donor:** Friends of Neal Rodin Philadelphia Home Run Challenge*Co-Principal Investigators:***Salma Kaochar, PhD**

Baylor College of Medicine, Houston, TX

Nicholas Mitsiades, MD, PhD

Baylor College of Medicine, Houston, TX

Goal: *To determine the potential for targeting master regulators of lipid and cholesterol synthesis as a novel treatment strategy in prostate cancer***Award Donors:** Edelman Family Foundation, Jamie Salter, and various other donors**2019 PCF Special Challenge Awards***Principal Investigator:***Michael Hofman, MBBS**

Peter MacCallum Cancer Centre, Melbourne, Australia

Goal: *To develop a prostate cancer imaging and theranostics centre of excellence that will accelerate clinical development of new prostate cancer theranostics and provide education and leadership to clinicians globally for successful use of these new radioligand and PET imaging technologies in patients***Award Donor:** CANICA AS*Co-Principal Investigators:***Alicia Morgans, MD, MPH**

Northwestern University, Chicago, IL

Charles Ryan, MD

University of Minnesota, Minneapolis, MN

Goal: *To investigate differences in cognitive side effects from treatment with darolutamide vs. enzalutamide in patients and identify risk factors for cognitive impairment***Award Donor:** Bayer*Co-Principal Investigators:***Paul Nghiem, MD, PhD**

University of Washington, Seattle, Washington

Peter Nelson, MD

University of Washington, Seattle, Washington

Goal: *To identify new treatment strategies for Merkel cell carcinoma and neuroendocrine prostate cancer, including strategies to improve the efficacy of immunotherapies***Award Donor:** The Odyssey Group Foundation*Co-Principal Investigators:***Karen Sfanos, PhD**


Johns Hopkins University, Baltimore, MD

Tamara Lotan, MD

Johns Hopkins University, Baltimore, MD

Franklin Huang, MD, PhD

University of California, San Francisco, San Francisco, CA

Goal: *To determine whether differences in the immune system contribute to prostate cancer incidence and mortality disparities in African American men***Award Donors:** Foundation 14, Don Mullen, Neil DeFeo, Michael and Patricia Berns, Estate of Calvin Patterson

Consolidated Statement of Financial Position

December 31	Without Donor Restrictions	With Donor Restrictions	2019 Total	2018 Total
ASSETS				
Cash and Cash Equivalents	\$ 9,875,775	\$ 3,875,073	\$ 13,750,848	\$ 20,694,813
Pledges Receivable (Net)	16,439,127	14,732,927	31,172,054	27,619,136
Prepaid Expenses and Other Assets	230,858	-	230,858	1,009,073
Property and Equipment (Net)	1,115,808	-	1,115,808	1,660,133
Total Assets	\$ 27,661,568	\$ 18,608,000	\$ 46,269,568	\$ 50,983,155
LIABILITIES AND NET ASSETS				
Liabilities				
Accounts Payable	\$ 591,061	\$ -	\$ 591,061	\$ 783,154
Accrued Liabilities	1,632,070	-	1,632,070	2,298,474
Deferred Revenue	30,000	-	30,000	50,000
Grants Payable	22,369,031	-	22,369,031	22,589,282
Total Liabilities	24,622,162	-	24,622,162	25,720,910
Net Assets				
Without Donor Restrictions	3,039,406	-	3,039,406	7,887,245
With Donor Restrictions	-	18,608,000	18,608,000	17,375,000
Total Net Assets	3,039,406	18,608,000	21,647,406	25,262,245
Total Liabilities and Net Assets	\$ 27,661,568	\$ 18,608,000	\$ 46,269,568	\$ 50,983,155

Consolidated Statement of Activities

Year Ended December 31	Without Donor Restrictions	With Donor Restrictions	2019 Total	2018 Total
Revenue and Public Support				
Grants and Contributions	\$ 38,009,305	\$ 7,208,000	\$ 45,217,305	\$ 42,068,134
Interest and Dividends	190,896	-	190,896	232,741
Other Loss	(688,762)	-	(688,762)	(274,082)
Net Assets Released from Donor Restrictions	5,975,000	(5,975,000)	-	-
Total Revenue and Public Support	43,486,439	1,233,000	44,719,439	42,026,793
Expenses				
Program Services:				
Research Grants	29,207,005	-	29,207,005	28,275,948
Compensation, Benefits, and Payroll Taxes	4,515,337	-	4,515,337	3,972,609
Global Scientific Conferences, Unpublished Data, and Knowledge Exchanges	2,174,354	-	2,174,354	2,091,212
Outreach, Events, and Meetings	1,162,163	-	1,162,163	882,407
Professional Fees	817,501	-	817,501	895,647
Media, Public Relations, and Publications	671,813	-	671,813	788,133
Depreciation and Amortization	476,396	-	476,396	466,852
Travel, Meals, and Entertainment	335,016	-	335,016	335,641
Office Expenses	307,675	-	307,675	228,654
Occupancy	178,532	-	178,532	180,390
Total Program Services:	39,845,792	-	39,845,792	38,117,493
Supporting Services:				
Management and General:				
Compensation, Benefits, and Payroll Taxes	2,031,124	-	2,031,124	1,983,550
Office Expenses	865,440	-	865,440	858,766
Professional Fees	305,913	-	305,913	411,229
Occupancy	252,023	-	252,023	164,525
Travel, Meals, and Entertainment	121,505	-	121,505	72,596
Depreciation and Amortization	82,940	-	82,940	71,296
Media, Public Relations, and Publications	55,948	-	55,948	30,073
Total Management and General:	3,714,893	-	3,714,893	3,592,035
Fundraising:				
Travel, Meals, and Entertainment	1,545,876	-	1,545,876	1,109,413
Outreach, Events, and Meetings	1,239,406	-	1,239,406	1,659,027
Compensation, Benefits, and Payroll Taxes	1,146,412	-	1,146,412	532,810
Office Expenses	385,696	-	385,696	380,177
Professional Fees	212,591	-	212,591	157,198
Media, Public Relations, and Publications	197,696	-	197,696	1,123
Occupancy	31,912	-	31,912	22,322
Depreciation and Amortization	14,004	-	14,004	8,682
Total Fundraising:	4,773,593	-	4,773,593	3,870,752
Total Expenses	48,334,278	-	48,334,278	45,580,280
Change in Net Assets	(4,847,839)	1,233,000	(3,614,839)	(3,553,487)
Net Assets - Beginning of Year	7,887,245	17,375,000	25,262,245	28,815,732
Net Assets - End of Year	\$ 3,039,406	\$ 18,608,000	\$ 21,647,406	\$ 25,262,245

Consolidated Statement of Cash Flows

Year Ended December 31	2019	2018
CASH FLOWS FROM OPERATING ACTIVITIES:		
Change in Net Assets	\$ (3,614,839)	\$ (3,553,487)
Adjustments to Reconcile Change in Net Assets to Net Cash Used In Operating Activities:		
Change in Present Value Discount on Pledges Receivable	(1,005)	415,854
Depreciation and Amortization	573,340	546,830
(Increase) Decrease in:		
Pledges Receivable	(3,551,913)	(438,565)
Prepaid Expenses and Other Assets	778,215	126,861
Increase (Decrease) in:		
Accounts Payable	(192,093)	(536,626)
Accrued Liabilities	(666,404)	381,769
Deferred Revenue	(20,000)	(50,000)
Grants Payable	(220,251)	(23,564)
Net Cash Provided by (Used In) Operating Activities	(6,914,950)	(3,130,928)
CASH FLOWS USED IN INVESTING ACTIVITIES:		
Purchase of Property and Equipment	(29,015)	(341,223)
Net Decrease in Cash and Cash Equivalents	(6,943,965)	(3,472,151)
Cash and Cash Equivalents - Beginning of Year	20,694,813	24,166,964
Cash and Cash Equivalents - End of Year	\$ 13,750,848	\$ 20,694,813

Independent Auditor's Report

To the Board of Directors
Prostate Cancer Foundation

Report on the Consolidated Financial Statements

We have audited the accompanying consolidated financial statements of the Prostate Cancer Foundation, which comprise the consolidated statement of financial position as of December 31, 2019, and the related consolidated statements of activities, functional expenses and cash flows for the year then ended, and the related notes to the consolidated financial statements.

Management's Responsibility for the Consolidated Financial Statements

Management is responsible for the preparation and fair presentation of these consolidated financial statements in accordance with accounting principles generally accepted in the United States of America; this includes the design, implementation, and maintenance of internal control relevant to the preparation and fair presentation of consolidated financial statements that are free from material misstatement, whether due to fraud or error.

Auditors' Responsibility

Our responsibility is to express an opinion on these consolidated financial statements based on our audit. We conducted our audit in accordance with auditing standards generally accepted in the United States of America. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements are free from material misstatement.

An audit involves performing procedures to obtain audit evidence about the amounts and disclosures in the consolidated financial statements. The procedures selected depend on the auditor's judgment, including the assessment of the risks of material misstatement of the consolidated financial statements, whether due to fraud or error. In making those risk assessments, the auditor considers internal control relevant to the entity's preparation and fair presentation of the consolidated financial statements in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the entity's internal control. Accordingly, we express no such opinion. An audit also includes evaluating the appropriateness of accounting policies used and the reasonableness of significant accounting estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

Opinion

In our opinion, the consolidated financial statements referred to above present fairly, in all material respects, the consolidated financial position of the Prostate Cancer Foundation as of December 31, 2019, and the changes in its consolidated net assets and its cash flows for the year then ended in accordance with accounting principles generally accepted in the United States of America.

Emphasis of Matter

As discussed in Note 10 to the consolidated financial statements, the recent COVID-19 pandemic in the United States and worldwide has resulted in reduced economic activity and market declines. As the extent and duration of the future impact to Prostate Cancer Foundation are uncertain, no adjustments were necessary to the consolidated financial statements, and our opinion is not modified with respect to this matter.

Report on Summarized Comparative Information

We have previously audited Prostate Cancer Foundation's 2018 consolidated financial statements, and we expressed an unmodified audit opinion on those audited consolidated financial statements in our report dated April 8, 2019. In our opinion, the summarized comparative information presented herein as of and for the year ended December 31, 2018 is consistent, in all material respects, with the audited consolidated financial statements from which it has been derived.

Green Hasson & Janks LLP

May 15, 2020
Los Angeles, California

2019 Supporting Partners

PCF is grateful for our major corporate partners and pharmaceutical company supporters. Contributions, campaigns, and educational initiative funding from these organizations are enabling PCF to move closer to a world without prostate cancer.



The John Black Charitable Foundation



Pharmaceutical Company Supporters



Board of Directors and Leadership Team

Board of Directors

Michael Milken
Founder and Chairman
Prostate Cancer Foundation

Emilio Bassini
Managing Principal
Bassini & Company

James C. Blair, PhD
Partner
Domain Associates, LLC

Steven A. Burd
Founder and Chief Executive
Officer
Burd Health LLC

Neil P. DeFeo
Executive Partner
Nonantum Capital Partners

David A. Ederer
Chairman
Ederer Investment Company

Jonathan Evans
President
Evans & Co., LLC

R. Christian B. Evensen
Managing Partner
Flintridge Capital
Investments, LLC

Peter T. Grauer
Chairman
Bloomberg LP

The Reverend Rosey Grier
Milken Family Foundation

Stein Erik Hagen
Chairman
Orkla ASA

Stuart Holden, MD
Clinical Professor of Urology
David Geffen School of
Medicine,
Spielberg Family Chair of Urologic
Oncology,
Associate Director, UCLA Institute
of Urologic Oncology

Clark Howard
Syndicated TV and Radio Host

The Honorable Earle I. Mack
Senior Partner
The Mack Company

Shmuel Meitar
Chairman and Founder
Aurec Capital

Lori Milken
Vice President
Prostate Cancer Foundation

Christopher J. Moran
Chairman
Moran Group of Companies
Chairman
Co-Operation Ireland

Henry L. Nordhoff
Chairman and
Chief Executive Officer
Banyan Biomarkers, Inc.

Drew Pinsky, MD
Internist, Addictionologist,
Radio and Television Host

Neal I. Rodin
Chairman
International Financial
Company, LLC
Chairman
RREI, LLC

Jason J. Safriet
Managing Director
Head of Security Sales
Credit Suisse

Richard V. Sandler
Partner
Maron & Sandler
Executive Vice President
Milken Family Foundation

Thomas S. "Tad" Smith, Jr.
Former President & CEO
Sotheby's

Roxann Taylor
Former Senior Managing Director
Amherst Holdings LLC

Paul Villanti
Executive Director, Programs
Movember Foundation

Andrew C. von Eschenbach, MD
President, Samaritan Health
Initiatives Inc.
Former Commissioner, Food and
Drug Administration
Former Director, National Cancer
Institute
Senior Fellow, Milken Institute

Kneeland Youngblood, MD
Founding Partner
Pharos Capital Group

Jeff Zisk
Managing Director
Surrey Ventures

Leadership Team

Jonathan W. Simons, MD
President and
Chief Executive Officer

Ralph Finerman
Chief Financial Officer,
Treasurer, and Secretary

Howard R. Soule, PhD
Executive Vice President,
Chief Science Officer

Stuart Holden, MD
Medical Director

Christine N. Jones
Chief Operating Officer

Helen Hsieh
Senior Vice President
Finance and Administration

Benjamin Engel
Chief Development Officer

Jan Haber
Vice President
Events

Julie DiBiase
Vice President
Content

Rebecca Levine
Chief of Staff, Vice President,
Government Affairs

Kathryn Schwertfeger
General Counsel



In Memory of
David H. Koch
1940–2019

David Koch was one of the world's most generous philanthropists and a great friend to the Foundation, contributing a **stunning \$50 million** to PCF's cutting-edge prostate cancer research and saving countless lives. Koch served on the Prostate Cancer Foundation Board of Directors from 1995 to 2019.

“David was a partner of ours in philanthropy and research. His contributions to medical research will live on forever; they have and will continue to benefit millions of Americans and others around the world. We will miss his sense of humor, his wisdom, and his insightfulness.”

– *Mike Milken*
Chairman, Prostate Cancer Foundation